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MECHANISMS OF IFN-γ AND CEFTAZIDIME INTERACTION 




 Burkholderia pseudomallei is a Gram negative, facultative intracellular pathogen which 
infects both phagocytes and non-phagocytes and causes severe acute infections in humans and 
animals.  Due to its inherent resistance to many classes of antibiotics, new therapies are needed 
which can supplement or substitute for conventional treatments in order to combat this emerging 
infectious disease.  We have previously shown that interferon-gamma (IFN-γ) can interact with 
the conventionally administered antibiotic, ceftazidime, to synergistically control intracellular 
bacteria burden of Burkholderia infected macrophages.  The goal of the studies present d here 
was to determine the mechanism by which IFN-γ and ceftazidime exert their synergistic effect. 
 After investigating several potential mediators of immuno-antimicrobial synergy, we 
showed that IFN-γ stimulation of macrophages led to increased generation of reactive oxygen 
species (ROS), which led us to hypothesize that IFN-γ induced ROS may interact with 
ceftazidime to control intracellular bacterial burden.  We next found that ROS scavenging 
antioxidants such as N-acetylcysteine (NAC) and reduc  glutathione (GSH) were capable of 
reversing the IFN-γ and ceftazidime synergistic effect, while the ROS-inducing drug buthionine 
sulfoximine (BSO) could not only potentiate the synergy, but could completely substitute for 
IFN-γ to synergize with ceftazidime and control intracellular bacterial burden.  These results 
were consistent with a ROS interaction with ceftazidime.  We further showed that IFN-γ 
prevented vacuolar escape and actin polymerization, a fi ding which was recapitulated with 
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BSO.  Taken together, these results suggested that generation of IFN-γ induced ROS responses 
synergized with ceftazidime to enhance control of intracellular bacterial burden.  IFN-γ induced 
ROS was also responsible for preventing vacuolar escape and therefore may have limited 
intracellular replication and spread of infection. 
 In the second half of our study we identified and then investigated the separate and 
compartmentalized contributions of IFN-γ and ceftazidime to the overall synergistic effect.  We 
determined that ceftazidime alone controlled extracellular killing in our macrophage infection 
model while IFN-γ alone controlled the killing of Burkholderia in the intracellular compartment.  
We confirmed a role for IFN-γ induced ROS responses to kill intracellular bacteria and control 
intracellular replication, though we also conclude that other IFN-γ-dependent and ROS-
independent pathways are at play.  Overall we suggest a new model to describe the dynamics of 
the classically used macrophage infection model.  We suggest that both intracellular and 
extracellular control of bacteria is required for the overall synergistic effect we see with 
combination of IFN-γ and ceftazidime.  Together our studies have implications for the use of 
IFN-γ, or other ROS-inducing drugs, as non-specific antibiotic potentiating agents for enhanced 
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CHAPTER 1:  LITERATURE REVIEW 
 
BURKHOLDERIA AND MELIOIDOSIS 
Epidemiology of melioidosis 
 B. pseudomallei is an aerobic, Gram negative bacillus, isolated from soil and water in the 
environment (1, 2).  It causes the emerging infectious disease called melioidosis, which is highly 
endemic in northern Australia and Thailand, less endemic in areas throughout southeast Asia, 
and appears sporadically in Central and South America as well as Africa (3-5) (see Figure 1.1).  
In northeast Thailand, melioidosis is the third leading cause of death due to infectious disease, 
after human immunodeficiency virus and tuberculosis (5).   
 
Figure 1.1:  Distribution of melioidosis around the world   Melioidosis is highly endemic in 
Thailand and northern Australia.  Other areas of endemic disease include southeast Asia with 
sporadic disease in parts of Africa as well as Central and South America (4). 
 
 Incidence rates greatly depend on geographical loction.  For example, Northeast 
Thailand has reported incidence of 4.4-21/100,000 (5, 6) while Northern Australia has reported 
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incidence of 19.6-102.4/100,000 (7-9), with similar ncidence rates in Taiwan (10) and Malaysia 
(11).  The incidence in Thailand seems to be increasing, as one study showed evidence of 
increased incidence rates from 8/100,000 in the year 2000 to 21.3/100,000 in the year 2006 (5).  
The variability of seasons also greatly impacts incidence rates.  For example, highest incidence 
rates occur after monsoonal rains (2-4, 6, 7, 10, 12, 13).  In the abnormally rainy 2009-2010 
season in northern Australia, incidence rose to a rate of 50.2/100,000 with incidence in 
indigenous populations as high as 102.4/100,000 (8).  Up until that season, the average incidence 
rate over the past 20 years had been 19.6/100,000 (8).   
 At the present time, inhalation, ingestion, and percutaneous inoculation are considered 
the three major routes of acquisition, though the proportional relevance of each is still 
speculative (2, 13, 14).  In cases where inoculation was reasonably recalled as percutaneous 
contact with muddy soil or water, clinical lesions were usually not discovered at the inoculation 
site, but in fact disseminated far from it (7).  These types of percutaneous infection followed by 
dissemination seems to be the most common route of inoculation, especially for rice farmers who 
have high exposure to muddy water and soil (2, 3).  Cases like these make it challenging to 
definitively identify the exact route of inoculation.  However, a 12-year study by Currie and 
colleagues suggests that inoculation through the inalation route may be increased during the 
rainy season due to monsoonal wind and rain (12). 
   Several risk factors are associated with contraction of melioidosis.  These include 
diabetes mellitus, chronic renal disease, chronic pulmonary disease, heavy alcohol use, and other 
immune-compromised individuals (3, 4, 6-9, 12).  Increased susceptibility of type 2 diabetes 
mice to B. pseudomallei infection has been linked to decreased macrophage function, particularly 
the ability to contain and kill intracellular Burkholderia (15).  Age does not seem to be a major 
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risk-factor since B. pseudomallei can infect persons of all ages, however the average infected 
individual is usually between 40-60 years old (2, 4-7, 10, 11). 
 
Clinical manifestations, diagnosis, and treatments for melioidosis 
 The incubation period for melioidosis is typically 1-21 days (7) though latent infections 
have surfaced decades after geographic exposure (16, 17).  Melioidosis can present as acute, sub-
acute, or chronic infection.  The most common presentation of melioidosis is respiratory 
pneumonia with other clinical manifestations including sepsis, abscess formation in skin or soft 
tissue, suppurative parotitis, peritonitis, arthritis, genito-urinary infection, encephalomyelitis, and 
others (3, 7, 13, 18, 19).   
 Melioidosis can sometimes be confused with tuberculosis in areas where B. pseudomallei 
is not endemic (20, 21).  Unfortunately a wrong diagnosis can be fatal since acute melioidosis 
can cause death within a few days.  Therefore corret and rapid diagnosis of melioidosis is 
extremely important.  B. pseudomallei is not considered normal microbial flora and there is no 
evidence of asymptomatic carriers, therefore a culture-positive specimen from an individual 
leads to a definitive clinical diagnosis of melioidsis (13, 22).  Diagnosis through culture, 
however, has its limitations because infected individuals may still culture negative for B.
pseudomallei (13, 23).  Polymerase chain reaction (PCR) is frequently used to confirm the 
identity of positive-cultures, though this method is imperfect as well, due to probe targets that 
cross-react with other non-virulent Burkholderia species (13).  Although the B. pseudomallei 
antigen in blood samples usually falls below the limit of detection of most immunofluorescent 
assays, Chantraitita and colleagues have shown that standard culture of blood samples prior to 
immunofluorescence greatly increases sensitivity and specificity of their detection system (23).  
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A reagent consisting of monoclonal antibody against B. pseudomallei exopolysaccharide and 
fluorescent secondary antibody was added to blood cultures on a slide and viewed by microscopy 
to detect fluorescence.  Their methods remarkably diagnosed melioidosis with a 97.4% 
sensitivity and 100% specificity (23). 
 B. pseudomallei is intrinsically resistant to penicillin, ampicillin, macrolides, 
aminoglycosides, rifamycins, polymyxin, and first and second generation cephalosporins (2, 4, 
21).  Chromosomally encoded, putative, resistance genes in B. pseudomallei account for all 
resistance to antibiotics and among others, encode for several β-lactamases and ten multidrug 
efflux pumps (24).  Aside from inherent antibiotic resistance, B. pseudomallei has also been 
shown to be resistant to innate immunity host-defenses and antimicrobial peptides (AMPs) (25, 
26).  Tandhavanant and colleagues found that B. pseudomallei was resistant to 200 µg/ml of 
lysozyme and 3 mg/ml of lactoferrin (25).  In one study, B. pseudomallei was shown to be 
resistant to both human neutrophil peptide-1 and human beta-defensin-2, an antimicrobial 
peptide of epithelial cells, at concentrations of 100 µg/ml (25).  On the other hand, B. 
pseudomallei was shown to be susceptible to the antimicrobial peptide LL-37 at concentrations 
of 6.25 µM (25). 
 Due to the inherent antibiotic resistance of B. pseudomallei, the first line antibiotic of 
choice to treat melioidosis is typically ceftazidime.  The current suggested antibiotic course for 
treatment of melioidosis includes a two-week minimum intravenous administration of 
ceftazidime or meropenem, followed by oral eradication herapy with trimethoprim and 
sulfamethoxazole for an additional three months (2, 3, 4).  However, even with antibiotic 
therapy, overall mortality rates have been reported between 20%-50%, dependent on 
geographical and seasonal variability (5, 7, 10, 11, 27).  Furthermore, greater than 10% of 
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patients can face recurrent infection, with around 75% of recurrent infections due to relapse 
versus reinfection (19, 27, 28).  Poor adherence to the antibiotic regimen is a major risk factor for 
relapse (19, 27). 
 
Similarities and differences between B. pseudomallei and B. thailandensis 
 B. thailandensis E264 is an environmental isolate from Thailand which was once 
classified as a strain of B. pseudomallei due to their similarities, but was eventually reclassified 
based on several key differences identified between th  species (29-31).  B. pseudomallei and B. 
thailandensis have a similar ability to replicate and survive intracellularly, and the mammalian 
cell response to both bacteria appears to be similar in regards to induction of cytokine response, 
costimulatory molecule expression, and differentiation bias towards a Th1 cell population (32).  
Furthermore, B. thailandensis and B. pseudomallei are morphologically and antigenically 
similar, and although they only differ in genetic sequence by 15 nucleotides, B. pseudomallei is 
considered highly virulent while B. thailandensis is considered to be less virulent (2, 30, 31).  In 
fact, B. thailandensis is considered to be at least 105 times less virulent than B. pseudomallei (29, 
30).  For example, while clinical isolate B. pseudomallei 1026b has been shown to kill Syrian 
golden hamsters with less than 12 colony forming units (CFU), the 50% lethal dose (LD50) of B. 
thailandensis E264 was 1.8 x 106 CFU (29).  In mice, the LD50 inoculum for B. pseudomallei 
was found to be 182 CFU in BALB/c mice versus around 109 CFU/mouse for B. thailandensis 
(30). 
 Differences in virulence between B. thailandensis and B. pseudomallei may depend on 
any number of small differences between the two organisms.  For instance, B. thailandensis 
secretions show proteolytic and siderophore activity, similar to B. pseudomallei 1026b, but also 
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shows lipase and lecithinase activities and are ablto assimilate L-arabinose (29, 30).  B. 
thailandensis also lacks the B. pseudomallei T3SS-1, though the exact role of T3SS-1 in 
virulence is still unknown (2, 33). 
 Another key difference between these two Burkholderia species may be their abilities to 
inflict damage on eukaryotic cells.  Early studies show that supernatants of B. thailandensis 
E264, which contained secretion products as well as bacterial antigens, were more cytotoxic to 
HeLa cells over a 48 hr period than supernatants from B. pseudomallei 1026b (29).  B. 
pseudomallei, however, appear to inflict more damage than B. thailandensis when bacteria exert 
their virulence from within infected macrophages.  Kespichayawattana found condensed and 
fragmented nuclei in 43% of macrophages after just 6 hours of infection with virulent B. 
pseudomallei, but just 23% of cells infected with less virulent, arabinose-assimilating 
Burkholderia (34). 
 B. pseudomallei and B. thailandensis may also differ in structure and components of their 
lipopolysaccharide (LPS) and capsular polysaccharide (CPS) (35, 36).  The lipid A moiety of B.
pseudomallei but not B. thailandensis is modified with 4-amino-4-deoxy-arabinose (35).  This 
modification may be a mechanism of immune system evasion through resistance to cationic 
antimicrobial peptides (35).  B. pseudomallei and B. thailandensis also differ in CPS.  Four 
putative CPS biosynthesis and export operons have been identified in B. pseudomallei.  The type 
I capsular polysaccharide, mannoheptose, associated with B. pseudomallei but not B. 
thailandensis, has been shown to inhibit C3b complement deposition and inhibit phagocytosis by 
polymorphonuclear leukocytes (37).  On the other hand, the type III CPS operon, identified in B. 
pseudomallei as well as B. thailandensis, was shown to be unnecessary for virulence in a Syrian 
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hamster model of melioidosis, but was suggested to contribute to the organisms’ abilities to live 
in the environment (36). 
 Due to its high infectivity, high associated mortality rates, and high level of inherent 
resistance to antibiotics, B. pseudomallei is classified as a potential bio-threat agent by the 
Centers for Disease Control and Prevention (CDC), containing most B. pseudomallei research to 
biosafety level 3 (BSL-3) facilities (2).  B. thailandensis, on the other hand, is considered a BSL-
2 organism and is frequently used as a model organism for in vitro pathogenesis studies of 
melioidosis (38). 
 
Intracellular lifestyle of Burkholderia 
 Burkholderia is a facultative intracellular organism which can infect and survive within 
professional and non-professional phagocytes as well as non-phagocytes (2, 26, 34, 39).  In fact, 
intracellular replication rates of B. pseudomallei can be similar to growth in liquid broth (34).  
The progressive steps associated with Burkholderia intracellular lifestyle are well known (Figure 
1.2).  Within minutes Burkholderia subverts host microfilaments to facilitate its internalization 
into membrane-bound vacuoles or phagosomes (40-44).  Within 2 hours, Burkholderia typically 
lyses the vacuole membrane to escape into the cytoplasm where it replicates, though some 
replication can begin in the vacuole (26, 40, 41, 45, 46).  In the cytoplasm Burkholderia 
polymerizes host cell actin and protrudes from membranes to spread from cell to cell (47, 48).  
Induction of host cell fusion and formation of multinucleated giant cells (MNGCs) is also 
thought to be a major mechanism of cell-to-cell spread (43). 
 MNGC formation is a rapid pathology that can develop in infected macrophages within 
6-8 hours time (49, 50).  Furthermore, MNGC formation is a clinically relevant histopathology 
 
that occurs in human melioidosis as well 
numbers of intracellular B. pseudomallei
spread through actin polymerization and membran
to formation of MNGCs with a correlation between intracellular bacterial burden and the rate of 
MNGC formation (34, 43). 
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spread is aimed at minimizing exposure to extracellular environments which may contain 
antibiotics and antibodies (2, 34, 48). 
 Several virulence factors are known to be required for the intracellular survival of 
Burkholderia.  B. pseudomallei contains three, type three secretion systems (T3SS) and in 
particular, T3SS gene cluster 3 (T3SS-3) is known to play an important role in virulence (2, 53).  
Known as the Burkholderia secretion apparatus (bsa), T3SS-3 is activated aftr ini ial contact 
with macrophages (54).  Furthermore, it is known to modulate intracellular survival and is 
essential for escape of endocytic vacuoles (43, 53). A study by Stevens and colleagues suggests 
that B. pseudomallei is capable of escaping the vacuole before phagosome-lysosome fusion 
events take place owing to observations of rare colocalization between wild-type B. 
pseudomallei and lysosome-associated membrane glycoprotein 1 (LAMP-1), a lysosomal marker 
which is enriched in phagolysosomes (53).  On the or hand B. pseudomallei which contained 
mutations to the bsa locus were almost exclusively colocalized with LAMP-1 and were 
contained within membrane-bound vesicles, signifying a failure to escape the vacuole and 
demonstrating the importance of T3SS-3 for vacuole escape (53).  Burtnick et. al. further 
evaluated the vacuolar escape of bsa mutants and found that they were capable of vacuolar 
escape, although escape was significantly delayed b 6 to 12 hours (55).  She also found that 
triple T3SS mutants also exhibited this delayed vacuolar escape phenotype, suggesting that 
T3SSs may enable rapid escape but are not essential for Burkholderia degradation of vacuole 
membranes and escape into the cytoplasm (55).  The T3SS-3 of B. pseudomallei likely displays 
virulence due to secretion of effector proteins through the secretion system apparatus into host 
cytoplasm.  Suparak and colleagues further investigated a T3SS-3 effector protein.  They found 
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that BipB, a translocator protein of the T3SS-3, played a role in MNGC formation and apoptosis 
of host cells (49). 
 B. pseudomallei also encodes six, type six secretion systems (T6SS) (56).  T6SS-1 is 
another putative virulence factor that may play important roles in the intracellular lifestyle of 
Burkholderia.  T6SS-1 gene cluster transcription is dependent on internalization by host cells and 
similar to T3SS-3 is important for intracellular growth, and MNGC formation (54, 57, 58).  
Burtnick et. al. showed that Hcp1 mutants lacking hemolysin co-regulated protein (Hcp1), a 
critical component of the T6SS apparatus as well as a secreted immunogenic protein, showed 
decreased growth rates in RAW 264.7 macrophages as well as decreased cytotoxicity and an 
inability to form MNGCs (57).  Hcp1 mutants were also less virulent in a Syrian hamster 
challenge model, again suggesting a role for T6SS-1 in the virulence of B. pseudomallei (57).  
Burtnick et. al. similarly showed that T6SS-1 was a virulence factor in B. mallei, a closely 
related species of B. pseudomallei.  They showed that T6SS-1 was required for actin tail 
polymerization and MNGC formation (59).  Burtnick and Brett found that T6SS-1 gene 
expression, as measured by Hcp1 production, was negativ ly regulated by the divalent cations 
iron and zinc for both B. mallei and B. pseudomallei, but not B. thailandensis (60).  This finding 
is consistent with increased T6SS-1 expression in host environments such as phagosomes or 
phagolysosomes which often contain limited nutrients (60).  T6SS-5 has also been implemented 
in MNGC formation and virulence due to VgrG-5, a T6SS-5 effector protein (50). 
 Eventually, intracellular B. pseudomallei replicates to such numbers inside cells that it 
ruptures the macrophage, releasing bacteria back into the extracellular space to re-infect healthy 
cells (40).  The entire progression of intracellular infection can be so rapid that certain clinical 
isolates of B. pseudomallei can invade, escape vacuoles, replicate and rupture macrophages all 
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within 120 minutes (40).  Other studies have confirmed rapid cell destruction from B.
pseudomallei infection and found that B. pseudomallei could cause severe cytotoxicity to 
cultures of in vitro macrophages---up to 20-60% cell d struction by 24 hours post-infection (45, 
61, 62). 
 Aside from cell damage through cytotoxicity or rupt re, B. pseudomallei has been shown 
to induce apoptotic-like appearance in macrophages such as condensed and fragmented nuclei, 
positive phosphatidylserine staining, and DNA breakage (34).  In one study, condensed and 
fragmented nuclei were seen in 43% of macrophages aft r just 6 hours of infection with B. 
pseudomallei (34). 
 However, since the time of that publication, scientists have significantly advanced their 
awareness of programmed cell death beyond the simple apoptosis-necrosis paradigm and have 
characterized the nuances of the several different types of programmed cell death.  Apoptosis is 
characterized as a caspase-3 and caspase-7 dependent, a ti-i flammatory mode of cell death with 
orderly dismantling and compartmentalization of cellular contents (42, 63-65).  On the other 
hand, pyroptosis is defined as a caspase-1 dependent, proi flammatory programmed cell death 
that results in pore formation in the plasma membrane nd release of intracellular contents (42, 
63-65). 
 Armed with new awareness of the different kinds of pr grammed cell death, others have 
more recently described Burkholderia-induced macrophage cell death as pyroptosis due to the 
proinflammatory nature of the programmed cell death, rather than apoptosis which is typically 
anti-inflammatory (42, 63).  For example, Sun and colleagues found that B. pseudomallei 
induced caspase-1 dependent cell death in macrophages, causing a release of proinflammatory 
cytokines IL-1β and IL-18 into extracellular milieu (42).  T3SS-3 was found to be necessary for 
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the rapid killing of macrophages which suggested that T3SS-3 effector proteins may be 
responsible for induction of cell death (42).  Sun also postulated that rapid killing of 
macrophages by B. pseudomallei was ironically a mechanism to evade death itself--a sort of kill 
or be killed situation (42).  Studies by Miao et. al. confirmed a role for caspase-1 dependent 
pyroptosis in B. thailandensis infection but unlike Sun, proposed pyroptosis as a host defense 
mechanism to eliminate intracellular Burkholderia rather than a bacterial defense to avoid killing 
by macrophages (63).  Breitbach et. al. also suggested that caspase-1 dependent macrophage 
death is a host survival adaptation to limit the intracellular niche for bacterial replication (66).  
They found that caspase-1 was actually essential for the resistance of C57BL/6 mice to B. 
pseudomallei infection since caspase 1 -/- mice showed rapid mortality and increased bacterial 
burden compared to wild type mice (66). 
 
HOST RESPONSE TO BURKHOLDERIA 
Immune response to Burkholderia infection 
 There are several lines of evidence which suggest that B. pseudomallei, in many ways, 
fails to activate a strong immune response in macrophages.  B. pseudomallei stimulation of 
macrophages fails to induce inducible nitric oxide synthase (iNOS), a key enzyme and 
antimicrobial mediator of macrophages that produces nitric oxide (NO•), a reactive nitrogen 
species (RNS) (67, 68).  Utaisincharoen also observed a 10x weaker activation of RAW 264.7 
macrophage cells as well as slower kinetics of exprssion of iNOS and tumor necrosis factor 
alpha (TNF-α) due to stimulation with B. pseudomallei compared with Escherichia coli or 
Salmonella typhi (69).   
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 The properties of B. pseudomallei LPS and CPS may account for its failure to sufficiently 
activate the antimicrobial properties of macrophages (35, 37).  Matsuura and colleagues found 
that the LPS of B. pseudomallei was 100x less pyrogenic, 30x less toxic, and a 10x weaker 
stimulant of macrophage activation than Salmonella abortus typhi (70).  They proposed that the 
longer-chain fatty acids of the lipid A structure of B. pseudomallei may account for these 
differences (70).  A different study showed that the O-antigenic polysaccharide moiety of B. 
pseudomallei was accountable for a lack of activation due to inerference with Toll-like receptor 
(TLR) signaling and specifically the MyD88-independt pathway, which is responsible for 
iNOS expression (68).  Although several types of LPS have been identified in B. pseudomallei, 
each with distinct antigens, no association has been found between LPS serotype and clinical 
presentation or outcome of disease (71).  Further studies will be required to determine the 
specific role of LPS types in the pathogenesis of melioidosis (71).  In summary, the immune 
response to B. pseudomallei may be less robust than other Gram negative pathogens in some 
aspects, however a properly functioning immune system is still the host’s best hope for 
resistance to B. pseudomallei and several cell types and cytokines in particular, h ve been shown 
to be protective. 
 Macrophages are one such cell type that are essential for control of acute B. pseudomallei 
infection, as intravenous delivery of liposomal clodr nate, a macrophage depleting drug, resulted 
in greatly increased mortality rates in both C57BL/6 and BALB/c mice (72).  In another study, 
by Haque et. al., macrophages were found to play an important role in acute phase infection 
presumably through production of IL-12 and IL-18 cytokines which are important inducers of 
IFN-γ, and are themselves essential for resistance (73). 
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 Neutrophils are another cell type which play an essential role in control of B. 
pseudomallei infection (74-77).  Neutrophils were rapidly recruited to the site of infection and 
were the predominant cell type associated with B. pseudomallei in mouse lung tissue at 36 hours 
post-aerosol infection (76).  Easton et. al. also found that activated neutrophils were critical for 
resistance to B. pseudomallei infection, even though their role was most important starting a few 
days after challenge (74).  Woodman et. al studied th  role of complement and serum 
opsonization on uptake and killing of Burkholderia in neutrophils.  They first found that both B. 
pseudomallei and B. thailandensis were extremely resistant to complement-mediated killing 
alone (75).  However, complement-opsonized bacteria were required for the NADPH oxidase-
mediated respiratory burst from neutrophils and subsequent intracellular killing of Burkholderia, 
suggesting an important role for complement after all (75). 
 B cells are known to have a minor and non-essential role in resistance to acute 
melioidosis.  Haque et. al. showed that µMT mice, which lack B cells, had equal mortality rates 
to B. pseudomallei infection compared to wild-type mice, suggesting that B cells are not required 
for protection against B. pseudomallei (73).  However, some studies have suggested that B cell 
antibody response may offer some protection against melioidosis (78, 79).  Additionally, sero-
positivity increases with age for children in northeast Thailand, and as many as 75% of children 
have been exposed to B. pseudomallei by the age of 4 (22).  As it turns out this sero-positivity 
may not have much of a protective effect.  Immune system memory to Burkholderia from a 
previous exposure may be inadequate to protect individuals against re-infection since one study 
showed that 25% of recurrent melioidosis cases werethought to be re-infection rather than 
relapse (28).  
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 T cells are another cell type that play an important role in melioidosis and seem to have a 
biphasic role in controlling resistance to Burkholderia (73).  Early in melioidosis T cells produce 
the critically important cytokine IFN-γ.   More information regarding the specific role of T cells 
as major producers of IFN-γ can be found in the section on the role of IFN-γ in B. pseudomallei 
infection (below).  In the later stages of infection, T cells are important for adaptive immunity.  
A study be Haque et. al. showed that B. pseudomallei primes antigen-specific CD4+ and CD8+  T 
cells however only mice depleted of CD4+  T cells, before and throughout a B. pseudomallei 
challenge model had greater mortality rates than control mice (73).  Mice depleted of CD8+ T 
cells did not have significantly different mortality rates compared to control mice, although the 
mean survival time was lower (73).  Taken together, these results suggest that T cells, but 
particularly CD4+ T cells play an important role in adaptive immunity during melioidosis. 
 
Mouse models of melioidosis 
 In regards to in vivo models of B. pseudomallei infection, C57BL/6 mice are considered 
approximately 100 fold more resistant to the particularly susceptible BALB/c strain, which can 
be killed with as few as 4 CFU (41, 80-82).  Regardless of their differences, both strains are 
valuable tools to study pathogenesis of melioidosis.  BALB/c mice are a better model for acute 
melioidosis because they mimic several aspects of human disease such as elevated IFN-γ and 
rapidly increasing bacteremia for several days before death (81).  Additionally, a correlation 
between increased IFN-γ and increased bacterial burden and severity of disease has been 
identified in both BALB/c mice as well as patients with melioidosis (82, 83).  On the other hand, 
C57BL/6 mice may serve as a model for chronic disease since they are able to survive for weeks 
after infection but still carry heavy bacteria loads in liver and spleen (81).  Furthermore, studying 
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C57BL/6 mice can provide insight into their resistance mechanisms and may help identify new 
drug targets or therapies to treat melioidosis.  For example, we know that a rapid and effective 
innate response contributes to C57BL/6 resistance si c  C57BL/6 mice can rapidly clear an 
infection that would kill BALB/c mice (41, 81). 
 
The role of IFN-γ in bacterial pathogenesis 
 IFN-γ is a cytokine secreted mainly by T cells and natural killer (NK) cells, which serves 
as one of the two essential activation signals for macrophages (84-86).  Macrophages activated 
by IFN-γ increase their antibacterial properties in several ways (84, 87).  They increase 
expression of NADPH phagocyte oxidase subunits, they restrict nutrients such as iron and 
tryptophan from the phagosome while enriching for copper, and they are primed for NO 
production (84, 85, 87).  Furthermore, IFN-γ and IFN-γ + LPS stimulated macrophages showed 
continuous phagosome-lysosome fusion events for up to 5-10 hours after stimulation, which led 
to great concentrations of lysosomal constituents in he phagolysosome (88). 
 Through activation of macrophages, IFN-γ has been shown to increase microbicidal 
activity against many intracellular pathogens, though the roles of IFN-γ are diverse (89).  During 
S. typhimurium infection of macrophages, IFN-γ reduces iron uptake, increases iron efflux, and 
increases expression of the siderophore and antimicrobial peptide lipocalin 2 (90).  In these 
ways, the macrophage limits the availability of iron, an essential nutrient for bacterial growth.  In 
Mycobacterium tuberculosis, IFN-γ is thought to have both beneficial and detrimental effects to 
macrophages depending on the level of intracellular infection.  IFN-γ inhibits M. tuberculosis 
replication during low-infection loads, but accelerat s cell death by necrosis in heavily infected 
macrophages (91).  In Listeria monocytogenes infected macrophages, IFN-γ stimulation has been 
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shown to increase the intracellular killing capacity of macrophages (92).  IFN-γ has also been 
shown to restrict intracellular replication of L. monocytogenes (92).  This effect was confirmed 
by Ouadrhiri and colleagues who showed that IFN-γ induced ROS and RNS were together 
responsible for restricting intracellular L. monocytogenes replication (93).   
 Several studies have also shown a role for IFN-γ prevention of vacuolar escape in a 
number of intracellular pathogens (92, 94, 95).  For instance, Myers et. al. showed that ROS, and 
to a smaller degree RNS, were required for the preventing L. monocytogenes from escaping 
vacuoles (95).   This study also showed that ROS and RNS inhibitors could partially reverse this 
effect, which is consistent with a ROS-mediated mechanism (95).    Similarly, Lindgren and 
colleagues found that IFN-γ activation of peritoneal exudate cells partially prevented Francisella 
tularensis from escaping phagosomes (94).  Furthermore they proposed that the bacteria which 
did escape were too damaged to replicate in the cytoplasm (94).  These results show an important 
role for IFN-γ to interfere with intracellular pathogen lifestyles in mammalian host cells, a 
mechanism that may increase killing of intracellular b cteria as well as prevent spread and 
further replication. 
  
The role of IFN-γ in B. pseudomallei infection 
 In a previous section we described several experiments that showed a failure of B. 
pseudomallei, by itself, to stimulate a strong immune response from macrophages.  However, 
several studies have shown a role for interferons t increase activation of B. pseudomallei-
stimulated macrophages.  For example, even though B. pseudomallei was unable to elicit iNOS 
expression in macrophages or control intracellular bacterial burden by itself, simultaneous 
stimulation of macrophages with exogenous IFN-β and B. pseudomallei led to greatly increased 
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levels of iNOS and increased killing of intracellular bacteria through NO• production (67).  
Similarly, although the LPS from B. pseudomallei interfered with MyD88-independent pathways 
and prevented iNOS production,  pre-activation of macrophages with IFN-γ and then subsequent 
infection increased expression of MyD88-independent pathways and increased expression of 
iNOS in macrophages (68).  Several other studies have shown an increased ability of 
macrophages to kill intracellular Burkholderia due to IFN-γ stimulation (32, 44, 66). 
 Both BALB/c and C57BL/6 strains of mice produce high levels of IFN-γ in response to 
B. pseudomallei infection, with BALB/c mice producing slightly higher levels both locally and 
systemically, but with slightly delayed expression, compared to C57BL/6 mice (82, 96, 97).  
High IFN-γ levels in BALB/c correlate to increased bacteria burden in tissue, suggesting that 
hyperproduction of IFN-γ in BALB/c mice may actually be more detrimental than protective 
(82).  Regardless, it is undisputed that IFN-γ, at some level, is necessary to control infection.  In 
fact, several studies have shown an absolutely obligatory role of IFN-γ for resistance to B. 
pseudomallei infection (72-74, 80).  For instance, IFN-γ was found to be essential for Taylor 
Outbred mouse resistance to B. pseudomallei as neutralizing antibody against IFN-γ lowered the 
lethal dose by 100,000 fold and caused great increases in bacterial burden in liver and spleen 
(80).  Additionally, IFN-γ neutralization in C57BL/6 mice led to greatly increased mortality rates 
while BALB/c mice retained significant protection, suggesting a different requirement for IFN-γ 
between these two breeds of mice (72).  Furthermore, while there was no role for iNOS in the 
C57BL/6 mouse resistance to B. pseudomallei, an important role was identified for nicotinamide 
adenine dinucleotide phosphate (NADPH) phagocyte oxidase and specifically macrophage 
NADPH oxidase to control infection (72). 
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 Other immune cells are the main sources of the necssary IFN-γ response.  Studies show 
that NK cells as well as CD3+ T cells are the major producers of IFN-γ due to B. pseudomallei 
infection (74, 96).  Antigen-unspecific bystander T cells, particularly CD8+ T cells, can also be 
activated to produce IFN-γ upon stimulation by cytokines IL-12 and IL-18 (73, 98). 
 One of the main antimicrobial mechanisms of IFN-γ activated macrophages is the 
degradation of internalized bacteria in the phagolys some.  Activated macrophages increase 
production of NADPH phagocyte oxidase subunits and subsequently increase intracellular ROS 
production (85, 86, 99, 100).  As phagosomes mature they fuse with lysosomes, exposing the 
phagocytosed bacteria to antimicrobial peptides (AMPs), lysozyme, and proteases (101).  While 
lysosomes are always acidic (pH ~4.8), phagosomes increase in acidity with increased lysosomal 
fusion events (102).  Phagosome-lysosome fusion can o cur within 20 minutes of Burkholderia 
uptake, which closely correlates to the minimum time required by B. pseudomallei to escape into 
the cytoplasm (39, 40, 45).  Those bacteria which take longer to escape are under attack by the 
toxic environment of the phagolysosome.  Puthucheary t. al. have shown the phagolysosome to 
have microbicidal activity against B. pseudomallei by showing that the number of bacteria inside 
phagolysosomes decreases with increased lysosome fusion (40). 
 Finally, IFN-γ has also been shown to interfere with normal Burkholderia pathogenesis.  
Both pre-treatment of macrophages with IFN-γ prior to infection or co-administration of IFN-γ 
with infection led to almost complete prevention of cell fusion and multinucleated giant cell 






REACTIVE OXYGEN SPECIES AND ANTIOXIDANTS 
Generation and detrimental effects of reactive oxygen species 
 The term “reactive oxygen species” refers to a group f highly reactive, short lived, 
partially reduced, oxygen-derived molecules which are capable of causing damage through 
reactions with nucleic acids, lipids, and proteins (87, 105, 106).  Some ROS such as superoxide 
anion (O2
•-) or hydroxyl radical (OH•) are also free radicals due to their unpaired electron, while 
others such as hydrogen peroxide (H2O2) are simply unstable and highly reactive. 
 ROS are formed at low levels in all cell types as a byproduct of cellular respiration, 
although phagocytes are capable of generating higher lev ls of ROS as an antimicrobial response 
through the nicotinamide adenine dinucleotide phospate (NADPH) phagocyte oxidase (100, 
101, 105, 107-109).  NADPH phagocyte oxidase is a large complex composed of five essential 
subunits.  The cytosolic proteins p47phox, p67phox, and Rac assemble with gp91phox and p22phox in 
the membrane (100, 108).  NADPH phagocyte oxidase as mbles primarily on phagosome and 
plasma membranes and is expressed in macrophages, neutrophils, and eosinophils (100, 108).  
Once assembled, NADPH phagocyte oxidase functions as an electron transporter to pump 
electrons into the compartment, reduce oxygen, and ge erate superoxide anion (100, 101, 108).  
It is estimated that the NADPH oxidase generates large mounts of superoxide, which could 
equate to concentrations of 2 µM in acidified phagosome compartments (101). 
 Since ROS are produced in all cells to varying extents, it is crucial for cells to degrade 
ROS or contain them in specialized compartments in order to avoid their toxic effects.  
Eukaryotes possess mechanisms to deal with ROS in essentially all compartments and organelles 
(105).  In just about every cell, superoxide anion is formed when oxygen accidentally gains an 
electron from the electron transport chain in mitochondria.  Superoxide dismutase (SOD) is an 
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enzyme which rapidly catalyzes the conversion of superoxide to hydrogen peroxide (H2O2), 
another form of ROS (105, 110, 111).  Of the known ROS, only H2O2 is thought to be stable 
enough to cross membranes, however the rates of H2O2 turnover inside cells is so rapid that the 
concentrations between intracellular and extracellular environments never equilibrate and can 
differ by a factor of ten (101, 105).  Catalases and peroxidases are responsible for degradation of 
H2O2 into water and oxygen.   
 Besides the directly toxic effects of superoxide to biomolecules, superoxide can also 
create more ROS.  It can react with iron-sulfur clusters, important enzymatic cofactors and redox 
sensors in the cell, releasing free iron that then reacts with hydrogen peroxide through Fenton 
chemistry to form deadly hydroxyl radicals (OH•) (105, 112, 113).  Hydroxyl radicals react 
almost instantly with biomolecules at the site of their creation and are considered an extremely 
toxic form of ROS (105). 
 
Antioxidants and ROS scavengers 
 Glutathione (GSH), or γ-glutamylcysteinylglycine, is the most abundant thiol and cellular 
antioxidant present in cells (114, 115).  GSH is formed in two steps.  The first reaction, which is 
also the rate limiting reaction, is catalyzed by glutamate cysteine ligase, also known as γ-
glutamylcysteine synthetase, which joins glutamate to cysteine (115-117).  The second step, 
catalyzed by glutathione synthetase, joins glycine to γ-glutamylcysteine to form GSH (115, 117).  
GSH synthesis takes place in the cytoplasm where thse enzymes are localized (118).  NAC is a 
precursor to GSH synthesis. 
 Intracellular GSH exists primarily in the reduced thiol form and has consistently high 
distribution within the cytoplasm, mitochondria, and ucleus of almost all eukaryotic cells (119, 
 
120).  Intracellular concentrations of GSH are typically between 1
(115).  GSH directly reacts with and 
also utilized by the family of glutathione peroxidases (GPx) to reduce H
GSSG, the oxidized, disulfide form of GSH is also pr duced from GPx reactions, but glutathione 
reductases quickly return glutathione to its reduce form using NADPH
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GSH also has antioxidant roles as a secreted peptide, especially in the fluid lining in the lungs 
(115).  GSH is extremely resistant to protease degradation as only one enzyme, γ-glutamyl 
transpeptidase, has been identified which is capable of GSH hydrolysis (121). 
 GSH is known to play an antioxidant role during oxidative stress.  Increased intracellular 
oxidative stress is associated with decreased intracellular glutathione, with the largest decreases 
of GSH occurring in the cytoplasm and nucleus (119, 122-124).  Mitochondrial GSH can also be 
depleted, though a low level of GSH is maintained in th s organelle to counter the constant low 
level of ROS produced in mitochondria by cellular respiration (119).  NAC also serves as an 
antioxidant and ROS scavenger, and can decrease the r spiratory burst exhibited by 
polymorphonuclear cells (125). 
 GSH biosynthesis is most commonly and effectively inhibited by the compound 
buthionine sulfoximine (BSO), a specific inhibitor f glutamate cysteine ligase (116, 126).  BSO 
depletes intracellular GSH by inhibiting new synthesis, but the length of time required to achieve 
its effects depends on the turnover rate of glutathione in a particular cell type as well as the 
permeability of the cells to BSO (126).  For example, treatment of cultured red blood cells with 
BSO (4 mM) for two hours resulted in 0.2 mM intracellular concentrations of BSO and greater 
than 90% inhibition of GSH biosynthesis, however detection of depleted GSH was not 
measurable until six hours post-treatment due to the slow turnover rate of GSH in red blood cells 
(126).  To contrast, in murine lymphoma cells, BSO (0.2 mM) took 12-15 hours to deplete GSH 
by greater than 90% while the same reduction in GSH content took 7.5 hours in mouse peritoneal 
macrophages (126).  Stevenson et. al. used 150 µM BSO for 20 hours to deplete hepatocyte GSH 
by 69% (123). 
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 BSO is also safe and effective for GSH depletion in vivo (126).  Griffith dosed mice up to 
32 mmol/kg without any signs of adverse effects.  Although BSO isn’t metabolized quickly in 
mice, it is excreted in urine, so a dose of 8 mmol/kg every four hours is suggested to keep the 
concentration of BSO at an inhibitory level in most ti sues (126). 
 Diethyl maleate (DEM) is another GSH depleting agent though it functions through a 
non-specific mechanism to directly deplete GSH rather an prevent de novo synthesis (127).  
DEM is not typically a first choice drug to deplete GSH because it has effects outside of the 
depletion of GSH which can complicate interpretation of experimental results (127).  
Furthermore since DEM works by direct depletion, cells sense the decreased presence of GSH 
and actually increase synthesis of GSH during treatm n  with DEM (127). 
  
ROS generation and degradation in bacteria 
 Bacteria not only produce high levels of ROS themslves, but they also face toxic levels 
of ROS from eukaryotic hosts.  Most intracellular bcteria have evolved mechanisms of 
resistance to ROS.  Target modification is rarely sen as a mechanism of resistance to ROS since 
the detrimental effects of ROS have atomic and chemical specificities to their targets unlike 
antibiotics with macromolecular specificity (109).  Instead, evasion of host ROS production, 
degradation of ROS, or simply repair from ROS damage re the most frequently observed 
mechanisms of resistance to ROS (109). 
 For the most part, pathways of ROS generation are similar between both eukaryotic and 
prokaryotic cells (105).  Bacteria produce significant levels of ROS through normal cellular 
processes, similar to eukaryotes.  E. coli has been shown to produce 15 µM H2O2 per second and 
about 5 µM superoxide anion per second (105).  Alsosimilar to eukaryotes, bacteria have similar 
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ROS degradation pathways involving SOD, catalases, and peroxidases (105).  If these 
antioxidant and ROS scavenging strategies fail, as little as 1 µM intracellular H2O2 can cause 
deadly levels of DNA damage (105).  As an example of the critical importance of cellular 
defenses against ROS, E. coli produce SOD in quantities approximately 4 orders of magnitude 
greater than needed (105). 
 Proteobacteria produce glutathione to eliminate ROS, similarly to eukaryotes (121).  
Bacteria contain high concentrations of intracellular GSH ranging from 0.1-10 mM (121).  
Increasing availability of cysteine may be able to increase GSH production in bacteria and 
increase protection against oxidative stress (100, 7 121, 128).  Bacteria may also be able to 
utilize exogenous sources of GSH.  A major mechanism of exogenous GSH utilization in 
bacteria is thought to occur through degradation by γ-glutamyl transpeptidase followed by 
cysteine or glycine salvage (121, 129, 130).  Uptake of whole reduced glutathione may also take 
place (131, 132). 
 Several studies have proven the ability of antioxidants, including NAC and GSH, to 
protect bacteria against killing by antibiotics (133-136).  Through mutant deletion of gshB, 
which encodes for a key enzyme in glutathione synthesis, Dhamdhere and colleagues showed 
that exogenously added GSH was able to protect bacteri  from both bactericidal and 
bacteriostatic antibiotics, suggesting the mechanism of GSH protection may be localized to the 
outer structures of bacteria (134).  Interestingly, endogenously produced GSH was actually 
detrimental to the protection (134).  Furthermore, a recent study showed that 10 mM GSH did 
not protect Staphylococcus aureus against ciprofloxacin, gentamicin, or chloramphenicol (137), 




ROS generation and degradation in B. pseudomallei 
 Specifically, Burkholderia possess several mechanisms by which they can defend against 
oxidative stress.  These include degradation through catalases and SOD enzymes, through 
scavenging molecules such as glutathione, sequestration of iron, and through transcriptional 
regulation of oxidative stress response proteins (OxyR and SoxRS).  B. pseudomallei expresses a 
dual, catalase-peroxidase enzyme (katG) which is important for resistance to killing by several 
pro-oxidant drugs (138).  KatG is transcriptionally regulated by OxyR under conditions of 
oxidative stress (138).  
 A study by Chieng et. al. investigated transcriptional changes to B. pseudomallei during 6 
hours of macrophage infection (45).  They surprisingly found that most oxidative-stress related 
genes, including katG, oxyR, and the general stress response alternative sigma factor, rpoS, were 
either down-regulated or remained similar to levels in bacteria that were grown in cell culture 
media alone (45).  This result suggests that B. pseudomallei is well-adapted to evade the 
oxidative environment of the phagolysosome, presumably by rapidly escaping into the cytoplasm 
(45). 
 B. pseudomallei also expresses at least one superoxide dismutase (SOD) enzyme which 
can convert superoxide anion (O2
•-) to hydrogen peroxide.  Vanaporn and colleagues idnt fied a 
copper and zinc dependent sodC enzyme from B. pseudomallei (139).  An sodC deletion mutant 
of B. pseudomallei exhibited increased sensitivity to killing by superoxide, decreased survival 
inside macrophages, and led to lower mortality rates in BALB/c compared with the wild-type 
control (139).  These results show the importance of sodC to B. pseudomallei intracellular 




Role of ROS as the mechanism of antibiotic killing 
 There has been considerable controversy over the last decade as to whether or not 
bactericidal antibiotics kill bacteria through a common ROS-mediated pathway, regardless of 
antibiotic target.  On the one hand, there have been numerous studies supporting a common 
mechanism of bactericidal antibiotics through ROS induction.  These studies suggest that 
antibiotics stimulate hyperactivation of the electron transport chain in bacteria which decreases 
the levels of NADH, increases the levels of superoxide anion, release of iron from iron-sulfur 
clusters, and generation of hydroxyl radicals through the Fenton reaction which eventually cause 
death due to irreparable damage to DNA (107, 140-143).   
 Aminoglycosides are one of the bactericidal classes of antibiotics thought to function 
through the common oxidative pathway for antibiotic killing.  Briefly, aminoglycoside 
interaction with the ribosome led to mistranslation of proteins, which were then misfolded in the 
periplasmic space, activating bacterial envelope stres  responses which then interfere with 
various metabolic pathways including the TCA cycle and electron transport chain (144). 
 Foti and colleagues studied the mechanism by which antibiotic ROS leads to irreparable 
DNA damage.  They found that guanine nucleotides were particularly susceptible to oxidation, 
forming 7,8-dihydro-8-oxyguanine (8-oxo-guanine) (141).  This molecule was potentially 
mutagenic because it could pair with either adenine or cytosine.  If mismatches arose close to 
one another in the DNA, double stranded breaks could ccur during glycosalase excision and 
repair (105, 141).  Shatalin et. al. confirmed that antibiotics caused double-stranded breaks in 
DNA, an effect which could be reversed by protection against oxidative stress (145). 
 Studies by Grant et. al showed that increased oxygen availability could increase hydroxyl 
radical formation in and killing of persister cells, a dormant and naturally resistant subpopulation 
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of bacteria (146).  Indeed, others agree that oxygen concentration is proportional to levels of 
ROS production (147).  Other evidence for oxidative killing by antibiotics came from studies by 
Wang and Zhao which showed that mutant E. coli deficient in either sodA, sodB, or katG, 
showed increased susceptibilities to fluoroquinolones (148).  Furthermore, the ROS scavenger 
thiourea was able to reduce the killing effectiveness of fluoroquinolones which is consistent with 
an oxidative pathway for antibiotic killing (148). 
 Goswami et. al. showed that both 10 mM ascorbic acid s well as 10 mM GSH partially 
protected E. coli from the killing effects of fluoroquinolones (135).  Furthermore, mutants 
deficient in catalase and peroxidase activities were significantly protected from ciprofloxacin 
killing, suggesting a role for oxidative stress in the mechanism of ciprofloxacin (135).  However, 
a separate study showed that GSH could protect E. coli against bacteriostatic drugs as well, 
which are not known to induce ROS-mediated death, suggesting a role for GSH protection 
beyond its antioxidant function (134). 
 More recent investigations into the notion of ROS mediated antibiotic killing show that 
ROS is not involved in antibiotic-mediated killing.  In a beautifully elegant experiment, Keren et. 
al. showed that the bacteria cells which had higher intracellular ROS levels due to bactericidal 
antibiotics, were not more likely to be killed (149).  Their study showed that hydroxyphenyl 
fluorescein (HPF) which many studies have used to measure intracellular ROS, was not an 
indicator of impending bacterial death (149).  Furthe more, thiourea, a commonly used ROS-
scavenger was only effective at protecting bacteria from low concentrations of antibiotics, but 
not higher, clinically relevant concentrations (149).  One criticism of this result is that the 
researchers did not increase the concentration of thiourea along-side increased antibiotic 
concentration.  It would be expected that as bacteria killing is increased with increasing 
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antibiotic concentration, a higher concentration of ROS-scavengers would be needed to provide 
the same level of protection.  Finally, they showed that E. coli grown and treated with antibiotics 
in completely anaerobic conditions were killed equally or better than bacteria grown and treated 
in aerobic conditions, an effect which is in direct contradiction to a ROS-mediated pathway for 
antibiotic-mediated death (149). 
 Another recent study by Imlay and colleagues confirmed that antibiotics, specifically 
ampicillin and norfloxacin were capable of the same efficiency of killing in anaerobic versus 
aerobic conditions, an effect which undermines a ROS-mediated pathway for antibiotic killing 
(150).  They went on to show that an E. coli mutant, lacking catalase and peroxidase activity, 
was more sensitive to fluoroquinolones but not aminoglycosides or β-lactams.  The mutant’s 
decreased sensitivity to fluoroquinolones was thougt to be due to the effects of 
fluoroquinolones on DNA metabolism (150).  They also showed that oxygen consumption, and 
therefore respiration, didn’t substantially increas in antibiotic treated E. coli, but in fact declined 
with kanamycin treatment.  Furthermore, they showed that β-lactams and fluoroquinolones failed 
to induce OxyR-controlled genes which were rapidly upregulated due to H2O2 alone, and 
confirmed a lack of antibiotic induced H2O2 by direct measure in the supernatants, using 
catalase/peroxidase mutants (150).  Finally, Ezraty and Barras also showed that E. coli mutants 
lacking both sodA and sodB or lacking oxyR were similarly sensitive to ampicillin or gentamicin 
compared to wild type bacteria (151). 
 The recent studies described above utilized both elegant and creative approaches to show 
that antibiotic-mediated cell death occurs independently of ROS.  However as ROS proponent 
James Collins points out, ROS has never been suggested to be the sole way in which antibiotics 
exert their killing effects (152).  In addition, these studies focused on one organism, E. coli.  It is 
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possible that other organisms respond differently to antibiotics.  Furthermore, these studies did 
not address the use of other antioxidants, besides thiourea, to reverse killing effects of 
antibiotics.  Therefore, there may still be a small role for ROS-mediated effects in antibiotic 
killing. 
 
Summary of literature review 
 The studies and results discussed in this chapter serve as background for the remaining 
chapters.  The current literature suggests a key rol  for IFN-γ stimulated responses in host 
defense against intracellular pathogens, especially through activation of macrophages to enhance 
their killing capabilities.  There is also a known role for ROS responses in host defense against 
bacterial pathogens.  Understanding connections between these pathways and their interactions 
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CHAPTER 2:  RESEARCH RATIONALE AND SPECIFIC AIMS 
 
 
RESEARCH OVERVIEW  
 This dissertation presents research aimed at gaining an understanding of the mechanism 
of immuno-antimicrobial synergistic killing of intracellular Burkholderia in the hopes that future 
treatments and therapies for melioidosis may enhance outcomes through targeting this 
mechanism.  In chapter 3 we explore mechanisms of immuno-antimicrobial synergy.  In chapter 
4 we examine the role of IFN-γ induced ROS to interact with ceftazidime and synergistically 
reduce bacterial burden of intracellular Burkholderia.  We also investigate the mechanism of 
IFN-γ interference with the normal intracellular lifestyle of Burkholderia.  In chapter 5 we 
discover a role for compartmentalized killing in immuno-antimicrobial synergy and therefore 
focus our investigations on the separate contributions of both IFN-γ and ceftazidime.  We also 




 In vivo, macrophages are an essential cell type for pr tection against Burkholderia 
infection, capable of direct elimination of the intracellular pathogen as well as secretion of 
cytokines IL-12 and IL-18 which are potent activators f other cells important for immunity to 
Burkholderia (1, 2).  However, in vitro studies show us that macrophages play very little role in 
controlling intracellular infection without sufficient activation.  For instance, Utaisincharoen 
showed a failure of macrophages to induce iNOS expression or reduce intracellular bacterial 
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burden when stimulated with B. pseudomallei alone (3).  The failure of B. pseudomallei to 
sufficiently activate macrophages is thought to be attributed to the structure and components of 
its LPS and polysaccharide (4, 5).  Low activation of immune responses may be a mechanism 
employed by Burkholderia to facilitate its survival in macrophages, perhaps impacting the long 
latency of chronic infections seen in some hosts (6, 7).  However, although B. pseudomallei is a 
poor activator of macrophages on its own, co-stimulation with Burkholderia and proper 
cytokines can strongly activate macrophages, resulting in greatly increased macrophage killing 
capacity (3, 8, 9).  Under these conditions of activ tion it is more understandable that 
macrophages in vivo play such an essential role for fighting infection.   
 Probably the most well known cytokine activator of macrophages is IFN-γ.  IFN-γ has 
been shown to be essential for protection against Burkholderia infection, through activation of 
macrophages and subsequent enhancement of their major icrobicidal effectors (1, 2, 10, 11).  
Despite the importance of IFN-γ and its effects of enhancing host immunity to pathogens, current 
treatment of melioidosis relies on antibiotic therapy lone. 
  
OVERALL THESIS SPECIFIC AIMS 
 Our lab understands the critical need for cytokine stimulation to increase macrophage 
killing potential against B. pseudomallei, and has taken the approach of combining the important 
immune stimulant, IFN-γ, with antibiotics in order to enhance elimination of the pathogen from 
in vitro and in vivo systems.  We previously found that IFN-γ synergized with ceftazidime to kill 
intracellular Burkholderia in infected macrophages and protect against lethal chal enge in mice 
(12).  This finding alone has implications for potential enhancement of therapy against 
melioidosis, however, uncovering the mechanism of this synergistic interaction could further 
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open new avenues for targeted treatments or immune adjuvants.  Therefore our first aim is given 
below: 
 
Aim 1 (Chapter 3 and 4):  Investigate the mechanism by which IFN-γ activation of 
macrophages synergizes with ceftazidime to kill intracellular bacteria.   
 Our hypothesis was that IFN-γ induced ROS could synergize with ceftazidime to kill 
intracellular bacteria.  In chapter 3 we explore potential mediators of immuno-antimicrobial 
synergy.  We determined a mechanism of the synergistic interaction in chapter 4, namely the 
macrophage response to IFN-γ which was indispensable for the synergy.  However, w  still 
knew very little about the individual contribution f ceftazidime to the synergistic interaction and 
wanted to further characterize the macrophage response to IFN-γ.  Therefore we crafted our 
second aim: 
Aim 2 (Chapter 5):  Investigate the specific and individual contributions of ceftazidime and 
IFN-γ to the synergistic killing. 
 Our hypothesis was that ceftazidime controlled extracellular bacterial burden and IFN-γ 
controlled intracellular bacterial burden.  In chapter 5 we characterized the role of 
compartmentalized killing in immuno-antimicrobial synergy.  We also propose a model to 
describe the synergistic interaction between ceftazidime and IFN-γ to control total bacterial 
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 B. pseudomallei is a facultative intracellular pathogen that causes severe infections in 
humans and animals.  Since Burkholderia is intrinsically resistant to many classes of antibio cs, 
new treatments are needed to combat melioidosis, the disease caused by Burkholderia infection.  
Our lab previously found that ceftazidime and IFN-γ combined treatment of infected 
macrophages led to synergistically reduced intracellular bacterial burden and increased survival 
of infected mice.  For several years our lab has investigated the mechanism of this synergistic 
interaction.  The studies presented in this chapter ar  some of our initial studies to identify a 
major mediator of the in vitro synergy. 
 Although IFN-γ stimulation increased CXCL10 protein secretion in a time-dependent 
manner, we found that synergy between ceftazidime and IFN-γ was still achievable in  
CXCL10 -/- bone marrow macrophages, suggesting that CXCL10 is not a major mediator of the 
synergistic interaction between the two treatments.  Another AMP, LL-37 was shown to 
synergistically inhibit Burkholderia growth, however only under contrived conditions that are 
not likely to occur in the macrophages or mice in which we see the synergistic interaction of 
ceftazidime with IFN-γ.  We next investigated IFN-γ induced ROS as a potential mediator of 
immuno-antimicrobial synergy.  We found that subinhibitory ceftazidime and H2O2 were able to 
synergistically inhibit bacterial growth but there was no synergistic interaction between 
bactericidal concentrations of both compounds.  We end the chapter with initial studies to 
quantitate the levels of intracellular ROS induced by ceftazidime in Burkholderia.  Although our 
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preliminary studies showed that ceftazidime could induce ROS in bacteria, recent studies show 
that the reagent that we used to measure ROS, hydroxyphenyl fluorescein (HPF), is not suitable 
for that purpose.  In conclusion, the results presented in this chapter were aimed at identifying a 
potential mediator of immuno-antimicrobial synergy.  This chapter presents valuable negative 
data which may help future scientists if they choose to study this topic. 
 
INTRODUCTION 
 B. pseudomallei is a Gram negative, facultative intracellular pathogen which causes 
melioidosis, a life-threatening infectious disease (1-3).  Since B. pseudomallei is intrinsically 
resistant to many classes of antibiotics (2, 4, 5), new therapies are greatly needed to combat this 
emerging infectious disease.  Burkholderia is also resistant to many antimicrobial peptides 
(AMPs) (6). 
 AMPs are small charged peptides (anionic or cationic) produced by many cell types as a 
mechanism of innate immunity for protection against pathogens (7, 8).  AMPs can kill 
microorganisms either through disruption of membranes or direct inhibition of cell wall 
synthesis, nucleic-acid and protein synthesis, or enzymatic activity similar to antibiotics (7).  
They can disrupt lipid bilayers either through coating the membrane and breaking it apart or 
through formation of pores which allow intracellular contents to leak out (7, 9-11).  AMPs can 
exert their antimicrobial effects intracellularly as well as extracellularly as secreted peptides and 
several studies have shown that AMPs can interact with antibiotics or other AMPs to increase 
antimicrobial activity against pathogens (12-16). 
 Some chemokines have been shown to display antimicrobial activity similar to AMPs.  In 
fact in a study of 30 human chemokines, 17 were shown t  have antimicrobial activity in vitro 
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including IFN-γ inducible CXCL10, which showed strong antimicrobial activity against E. coli 
and Staphylococcus aureus (17).  The strong positive charge of CXCL10 is thought to account 
for part of its antimicrobial activity against Gram negative and Gram positive bacteria (18). 
 LL-37 is a linear, α-helical, cationic AMP with broad antimicrobial activi y against Gram 
negative and Gram positive bacteria (7, 19).  LL-37 is produced by many cell types such as lung 
(20) and urinary tract (9, 21, 22) epithelial cells as well as some white blood cells including 
macrophages (23, 24).  The mechanism of action of LL-37 is to lie on membranes and actually 
induces the membrane to curve inward until a channel is formed (Figure 3.1) (7, 25).  Both 
exogenous LL-37 and endogenous cathelin-related AMP (CRAMP), a homolog of LL-37 in 
mice, have been shown to increase killing of intracellular mycobacteria in murine macrophages 
(26). 
 
Figure 3.1:  Mechanism of action of LL-37:  toroidal pore formation.  LL-37 attaches to 
membranes and induces the outer lipid monolayer to bend inward towards the inner lipid 
monolayer until a channel is formed.  LL-37 inserts in o the channel so that the hydrophobic 
portion of its structure is facing the lipids and the hydrophilic portion of its structure is facing the 




B. pseudomallei has been shown to be susceptible to LL-37 at concentrations of 6.25 µM (6).  In 
addition, the AMP has been shown to be more effectiv  at killing B. pseudomallei biofilms than 
high doses of ceftazidime (27). 
 Our lab has previously found that combined treatment of Burkholderia infected 
macrophages with ceftazidime and IFN-γ led to synergistically reduced intracellular bacterial 
burden (28).  For many years our lab has searched for the major mediator of this immuno-
antimicrobial synergy.  This chapter summarizes some f our findings during our search for the 
mediator of the synergistic interaction between ceftazidime and IFN-γ.  We caution our readers 
that in contrast to chapters 4 and 5, most of this c apter contains negative data and may not read 
as a logical flow from experiment to experiment.  At the time of these experiments, we were 
casting a wide net for potential mediators of the immuno-antimicrobial synergy and therefore we 
occasionally made abrupt stops to one line of reseach to focus on a new target.  With this said, 
we believe that the information presented in this capter is nonetheless important, especially for 
future scientists that may want to pick up this topic.  We hope that this chapter will provide the 
reader with a background of tried and failed leads for the mediator of immuno-antimicrobial 
synergy and may save time and frustration for future scientists that may find this information 
pertinent to their studies. 
 
MATERIALS AND METHODS 
Biochemicals. 
 Ceftazidime hydrate was purchased from Sigma-Aldrich (St. Louis, MO).  Other reagents 
included recombinant murine IFN-γ  (Peprotech, Rocky Hill, NJ), γ-D-Glu-mDAP (iE-DAP) and 
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muramyl dipeptide (MDP; InvivoGen, San Diego, CA), streptavidin-conjugated horseradish 
peroxidase (SA-HRP; Jackson ImmunoResearch Labs, Wet Grove, PA), tetramethylbenzidine 
(TMB; Sigma-Aldrich, St. Louis, MO), and hydroxyphenyl fluorescein (HPF, Life 
Technologies). 
 
Bacteria.   
 B. thailandensis E264 was used for these studies (29, 30).  Bacteria were grown in Luria-
Bertaini broth at 37°C with rotary shaking for 16 hours, and then stored at -80°C with 15% 
glycerol until needed.  Frozen vials of bacteria were thawed and diluted immediately prior to 
their use.  Bacteria were heat killed in an 80°C water bath for 1 hour, and then frozen at -20°C 
until needed. 
 
Cell lines.   
 RAW 264.7 macrophage cell line was purchased from American Type Tissue Collection 
(Manassas, VA).  Cell lines were maintained in complete media consisting of minimum essential 
media (MEM; Life Technologies) supplemented with 10% fetal bovine serum (FBS) (Atlas, Fort 
Collins, CO), 0.075% sodium bicarbonate (Acros organics, NJ), 1x nonessential amino acids, 
0.5x essential amino acids (Life Technologies), and 2 mM L-glutamine (Sigma-Aldrich).  
Antibiotic additions of 100 Units/ml Penicillin and 100 µg/ml Streptomycin (Life Technologies) 
were added to media for maintenance of cell lines but all experiments were conducted in 




 Female C57BL/6 and CXCL10 -/- mice were used for these studies.  All mice were 
between 6 to 12 weeks old at the time of their use and were housed under pathogen-free 
conditions. All animal studies were approved by the Institutional Animal Care and Use 
Committee at Colorado State University. 
 
Primary bone marrow macrophage culture. 
 Bone marrow macrophages were generated as previously de cribed (31).  Femurs and 
tibias were aseptically removed from mice, transferred to 50 ml conical tubes containing Hank’s 
buffered salt solution (HBSS) supplemented with 2% FBS, and kept on ice.  In a biosafety 
cabinet, bones were cleaned of tissue and bone marrow was flushed from the bones using needles 
and syringes filled with HBSS and supplemented with 2% FBS.  Bone marrow was gently 
resuspended with gentle pipetting and passed throug a 70 µm nylon filter (BD Biosciences 
Pharmingen, San Jose, CA).  Cells were centrifuged at 1200 rpm for 5 minutes at 4°C.  Then 
supernatant was removed and red blood cells were lysed using 2 ml of ammonium-chloride-
potassium (ACK) lysis buffer for 5 minutes, followed immediately by 20 mls of complete MEM 
with antibiotics and 10% L929-conditioned supernatats to dilute the lysis buffer.  Cells were 
again spun at 1200 rpm for 5 minutes at 4°C.  Remaining white blood cells were plated in 24-
well plates at a concentration of 2 x 106 cells/ml in complete MEM.  Cells were allowed to 
adhere to 24-well plates for 3 hours at 37°C and 5% CO2 after which, non-adhered cells were 
washed away three times with room-temperature HBSS supplemented with 2% FBS.  Complete 
media with antibiotics and 10% L929 conditioned media was reapplied to the cells and plates 
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were returned to the incubator.  Addition of 10% L929-conditioned media provided necessary 
growth factors for differentiation of bone marrow myeloid progenitor cells into the 
macrophage/monocyte lineage to enrich for these cells.  Adherent cells were incubated at 37oC 
and 5% CO2 until macrophages reached moderate confluency in wells (approximately 8-12 
days). 
 
Macrophage infection assay.  
 Macrophages were infected and treated as previously de cribed (28).  Briefly, 
macrophages were seeded into 24-well plates with complete MEM (see above) and allowed to 
adhere overnight.  After a 1ml wash with phosphate buffered saline (PBS), B. thailandensis was 
added to macrophages at a multiplicity of infection of 5 and incubated for 1 hour at 37°C in 5% 
CO2.  Aminoglycosides are not considered to penetrate mammalian cells in short time periods 
(32), so macrophages were exposed to high-dose kanamycin-sulfate (350 µg/ml) for 1 hour to 
kill extracellular bacteria.  After two 2 ml washes with PBS to remove kanamycin and dead 
bacteria, treatments were diluted in MEM, applied to macrophages, and incubated for 18 hours.  
Treatments consisted of individual drugs or combinatio s of the following:  ceftazidime (10 
µg/ml), IFN-γ (10 ng/ml), or the combination of both drugs.  Although ceftazidime was applied 
at 10 µg/ml to infected macrophage cell lines, it was applied at 3 µg/ml or 5 µg/ml to infected 
bone marrow macrophages because 10 µg/ml had too great of an effect at controlling 
intracellular bacterial burden on its own, and therefore made it harder to determine synergy with 
IFN-γ.  After the 18 hour treatment of infected macrophages, extracellular bacteria were washed 
off three times with 2 mls of PBS and macrophages wre lysed with 1 ml of sterile distilled 
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water.  Intracellular bacterial burden was then asses ed by plating serial dilutions of the lysates 
on LB agar followed by colony counts 24-48 hrs after plating. 
 
CXCL10 ELISA 
 Enzyme-linked immunosorbent assays (ELISA) were peformed to quantitate the 
concentration of CXCL10 in supernatants after infection and/or stimulation of RAW 264.7 
macrophages using a murine CXCL10 (IP-10) ELISA kit (Peprotech, Rocky Hill, NJ).  Anti-
CXCL10 capture antibody was diluted to 0.5 µg/ml in PBS and added to 96-well Nunc 
MaxiSorp plates (ebioscience, San Diego, CA).  Plates were covered and incubated overnight at 
room temperature.  The next day, wells of plates were washed three times with a solution of 
0.05% Tween 20 in PBS (wash buffer).  Wells were blocked with 1% bovine serum albumin in 
PBS for one hour at room temperature and then washed thr e times in wash buffer.  The 
CXCL10 standard was diluted in 0.1% bovine serum albumin in PBS with 0.05% Tween 20 
(diluent) and added to wells in duplicate.  The standard ranged from 8 ng/ml to 4 pg/ml.  
Samples were added to the plate and standards and samples were incubated for two hours at 
room temperature followed by three washes with wash buffer.  Detection antibody was diluted to 
0.25 µg/ml and added to wells for two hours at room te perature.  After the plates were washed 
three times with wash buffer, SA-HRP was diluted 1:5,000 in diluent and incubated in plates for 
30 minutes at room temperature.  Following another ree washes in wash buffer, TMB was 
added to wells at room temperature and the plates were read after color change on a 
spectrophotometer at 405 nm with a wavelength corretion set at 650 nm.  Sample 
concentrations were calculated off of the standard cu ve. 
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Bacteria killing assays 
 In order to determine if treatment of bacteria with one drug may enhance killing by a 
second, we used a bacteria killing assay and pre-treated E. coli with one drug before subjecting 
bacteria to the second drug.  In one set of experiments we pre-treated 125 µl of an overnight 
culture of E. coli with 50-75 ng/ml ceftazidime for 18 hours to induce filamentation.  Induction 
of filamentation of bacteria was confirmed by light microscopy.  Previous experiments had 
determined the resulting bacteria density to be roughly 3x107 CFU/ml after this 18 hour pre-
treatment period.  We then plated either filamentous r non-filamentous control bacteria into 
wells of a 96-well plate at a final density of 1x107 CFU/ml in tryptic soy broth (TSB).  The 
second treatment, LL-37 (15 µg/ml) was added to wells so that the total volume per well was 100 
µl.  Plates were incubated at 37°C with rotary shaking (200-250 rpm) for an additional 2-6 hours.  
Surviving bacteria were enumerated by plating serial dilutions of remaining bacteria on LB agar 
and counting colonies 24-48 hours later.  Another set of experiments were conducted in which E. 
coli was first pre-treated with LL-37 and then subjected to ceftazidime.  Non-filamentous E. coli 
was pre-treated with LL-37 (15 µg/ml) for 1 hour and then washed twice (TSB followed by 
1mM sodium phosphate buffer) to remove LL-37 with spin  at 10,000xg for 5 minutes at 20°C.  
Bacteria were added to 96-well plates at a density of 1x107 CFU/ml in wells and ceftazidime (50 
ng/ml) was added to wells.  Plates were incubated at 37°C with rotary shaking (200-250 rpm) for 
an additional 6 hours. 
 Bacteria killing assays were conducted with B. thailandensis to determine drug 
interactions which could enhance killing of bacteria over one drug alone.  Bacteria were grown 
to mid-log phase and plated in 96-well plates with treatment additions as indicated below 
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specific graphs of data.  After the indicated experim ntal period, surviving bacteria were 
enumerated by plating well contents on LB agar followed by colony counts 24-48 hours later. 
 
Flow cytometry. 
 B. thailandensis was grown to mid-log phase and then 1 ml aliquots were treated with 
ceftazidime (10 µg/ml) for two hours.  After the tratment period, 50 µl samples were taken from 
the 1 ml aliquots, spun down at 5000xg for 5 minutes at 23°C, and stained with 5 µM HPF for 30 
minutes at room temperature in the dark.  The totalvolume for staining was 150 µl.  After 
staining, the bacteria were washed twice with 1 ml of bacterial flow buffer and then immediately 
resuspended in 200-400 µl of bacterial flow buffer and run on flow cytometry.  Data was 
collected on greater than 50,000 cells per sample using a Gallios Flow Cytometer (Beckman 
Coulter, Brea, CA) and analyzed using FlowJo software version 7.6.5 (Tree Star, Ashland, OR).  
An untreated, unstained sample was used to set the ini ial voltages.  HPF signal in treated 
samples was compared to background levels in untreated but stained controls. 
 
Statistical analyses. 
 Means, standard error of the mean (SEM), and P-values were determined and plotted 
using Prism software version 5.00 (GraphPad, La Joll , CA).  For comparisons of two groups, a 
two-tailed Student’s t-test was used to determine statistically significant differences.  For 
comparisons of three or more groups the one-way anal sis of variance (ANOVA) was used 
followed by Tukey’s post test for multiple comparison .  Grouped data was analyzed by two-way 
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ANOVA and statistical synergy was determined as before (33) from the interaction P-value of a 
two-way ANOVA.  All differences were considered statistically significant for P < 0.05. 
 
RESULTS 
 IFN-γ stimulates CXCL10 production from macrophages.  Our lab had previously 
observed that ceftazidime and IFN-γ interacted to synergistically reduce intracellular b cterial 
burden inside Burkholderia infected RAW 264.7 macrophages (28) but not J774A.1 
macrophages.  In order to better understand the mechanism of synergy in RAW 264.7 
macrophages, we conducted a microarray to compare differences between gene expression in 
uninfected RAW 264.7 and J774A.1 cells following treatment with ceftazidime and IFN-γ.  The 
genes encoding CXCL10 and CXCL9 proteins, two chemokines with AMP-like properties (17, 
18), were high on the list of genes that were upregulated in RAW 264.7 macrophages but not 
J774A.1 cells, suggesting a potential role of these proteins as mediators of the immuno-
antimicrobial synergy.  Our studies turned to CXCL10, an IFN-γ induced protein and chemokine 
which may also display antimicrobial properties due to its cationic nature.  We first wanted to 
know whether or not IFN-γ could stimulate increased levels of CXCL10 in our macrophage cell 
line.  Therefore, we used an ELISA to determine levels of CXCL10 in supernatants following 
IFN-γ stimulation of RAW 264.7 macrophages.  We showed that IFN-γ stimulation greatly 
increased CXCL10 protein levels in the supernatants of uninfected macrophages (Figure 3.2).  
Although we measured extracellular protein levels, we assumed that intracellular levels would 
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Figure 3.2:  IFN-γ stimulates CXCL10 production from uninfected macrophages.  
Uninfected RAW 264.7 macrophages were stimulated for 18 hours with IFN-γ (10 ng/ml), iE-
DAP (10 µg/ml) and MDP (10 µg/ml), or heat killed B. thailandensis (1x107 CFU/ml).  After 18 
hours, supernatants were collected.  An ELISA was performed to determine the concentration of 
CXCL10 in the collected supernatants.  Statistical differences were assessed by one-way 
ANOVA, (a > b, P < 0.05).  Data are representative of two independent experiments run in 
triplicate. 
 
Notably, we also showed that neither nucleotide-binding oligomerization domain-containing 
protein 1 (NOD1) nor NOD2 agonists (iE-DAP and MDP, respectively) were capable of 
stimulating increased levels of CXCL10 (Figure 3.2).  This result suggests that bacteria 
peptidoglycan sensed intracellularly by NOD1 or NOD2 would be incapable of stimulating 
increased levels of CXCL10.  To confirm that bacterial cell wall components could not increase 
levels of CXCL10, we showed that heat killed Burkholderia were unable to elicit a significant 
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increase in CXCL10 (Figure 3.2).  Taken together thse results suggest that IFN-γ but not 
bacterial cell wall components stimulated increased CXCL10 production from uninfected 
macrophages. 
 After showing that IFN-γ increased CXCL10 production in uninfected macrophages, we 
next determined the extent of increased CXCL10 production in our infected macrophages treated 
with IFN-γ for 18 hours.  Again we found that IFN-γ increased CXCL10 expression as 
determined by an ELISA of supernatants from infected and treated RAW 264.7 cells (Figure 
3.3).  We also showed that CXCL10 protein levels increased over time in our Burkholderia 
infected macrophages (Figure A1).  Taken together our esults show that IFN-γ stimulation 
increased CXCL10 levels as measured in the supernatants of both uninfected and infected 
macrophages. 
 
 CXCL10 is not likely a major mediator of IFN-γ and ceftazidime immuno-
antimicrobial synergy.  Although we had shown that IFN-γ could stimulate high levels of 
secreted CXCL10 protein, we speculated that in our immuno-antimicrobial synergy, intracellular 
CXCL10 protein would be more likely to synergize with ceftazidime to affect intracellular 
bacterial burden.  We therefore conducted a macrophage infection assay using primary bone 
marrow derived macrophages from CXCL10 -/- or C57BL/6 control mice.  We rationalized that if 
CXCL10 was a major mechanism of immuno-antimicrobial synergy, macrophages unable to 
produce CXCL10 would be unable to synergistically control intracellular bacterial burden due to 
IFN-γ and ceftazidime treatment; or in other words, we would see a reversal of the synergistic 
61 
 
control of intracellular bacterial burden in Burkholderia infected macrophages.
CXCL10 Concentration in Supernatants























Figure 3.3:  IFN-γ stimulates CXCL10 production from Burkholderia infected 
macrophages.  RAW 264.7 macrophages were infected with B. thailandensis and treated for 18 
hours with IFN-γ (10 ng/ml).  After 18 hours, supernatants were colle ted.  An ELISA was 
performed to determine the concentration of CXCL10 in the collected supernatants.  Statistical 
differences were assessed by a two-tailed Student’s T-te t, (*P = 0.0306).  Data are 
representative of two independent experiments run in triplicate. 
 
  However, as shown in Figure 3.4, we found that synergy prevailed in CXCL10 -/- bone marrow 
macrophages.  This result suggested that CXCL10 is not a major mediator of the immuno-
antimicrobial synergy observed between IFN-γ and ceftazidime. 
 
 Bacteria killing due to interactions between LL-37 and ceftazidime depends on 
timing of treatment addition.  We had just shown that CXCL10 was not likely a major 
mediator of immuno-antimicrobial synergy, so we turned to another murine cationic AMP which 










































Figure 3.4:  Ceftazidime and IFN-γ show synergistic control of intracellular bacterial 
burden  in infected CXCL10 -/- bone marrow macrophages.  Primary bone marrow 
macrophages were cultured from CXCL10 -/- mice or C57BL/6 background-matched control 
mice.  Macrophages were infected with B. thailandensis and treated with ceftazidime (3 µg/ml or 
5 µg/ml) or IFN-γ (10 ng/ml) or the combination of both ceftazidime and IFN-γ for 18 hours.  
Intracellular bacterial burden was then assessed by plating serial dilutions of lysates on LB agar 
followed by colony counts 24-48 hours later.  Statis ical synergy between ceftazidime and IFN-γ 
was assessed by two-way ANOVA, *P < 0.05.  Data is pooled from two similar independent 
experiments (n >5) in order to increase sample size.
 
To test whether LL-37 and ceftazidime combination ca directly synergize to kill bacteria, we 
employed a bacteria killing assay which consisted of incubating bacteria with treatments for a 
designated time and then plating out surviving bacteria.  Because Burkholderia has inherent 
resistance to several AMPs (6), we used the more sensitive organism E. coli to first determine 
whether or not ceftazidime and LL-37 may interact to synergistically kill bacteria.  We first 
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showed that ceftazidime and LL-37 showed additive but not synergistic killing of E. coli (Figure 
A2).  We next wondered if pre-treating bacteria with one treatment would increase sensitivity to 
the other.  We rationalized that ceftazidime stress and damage to the bacterial cell wall may 
allow LL-37 better access to the cell membrane.  Therefore we pre-treated E. coli with low dose 
ceftazidime for 18 hours to induce filamentation, a typical morphology of Gram negative 
bacteria observed after exposure to low dose, cell wal  active, antibiotics.  Then we subjected 
these filamentous bacteria to LL-37 and were surprised to find that filamentous bacteria were 
resistant to the inhibitory effects seen by LL-37 trea ment of non-filamentous control bacteria 
(Figure 3.5).  We next rationalized that pre-treatment with LL-37 may disrupt the cell wall of 
bacteria and permit increased access of ceftazidime to inhibit cell wall synthesis.  We pre-treated 
bacteria with LL-37 and then added ceftazidime to the bacteria killing assay.  We were again 
surprised to see that bacteria pre-treated with LL-37 were more resistant to ceftazidime mediated 
inhibition of growth (Figure A3).  Taken together these results suggest that the timing of addition 
of LL-37 or ceftazidime has a great impact on their level of interaction to inhibit E. coli growth. 
 
 LL-37 and ceftazidime synergistically inhibit Burkholderia growth.  After showing 
additive killing effects of LL-37 and ceftazidime against E. coli, we next wanted to determine the 
interactions between these two compounds against Burkholderia.  We experimented with several 
different modifications to the bacteria killing assy, including different types of media and the 
concentration of treatments.  Since LL-37 is a cationic peptide whose mechanism of action is salt 
sensitive (20, 34), we tried using low-salt media such as 1 mM potassium or sodium phosphate 
buffer.  However, in these low-nutrient buffers, the bacteria would not grow and divide and 







































Figure 3.5:  Filamentous E. coli are more resistant to growth inhibition by LL-37.  E. coli 
was treated with low level ceftazidime (50 ng/ml) for 18 hours to induce filamentation.  These 
filamentous bacteria and non-filamentous controls were then exposed to LL-37 (15 µg/ml) in a 
96-well plate on a rotary shaker (200 rpm) for six hours with initial starting density of 1x107 
CFU/ml.  Surviving bacteria were enumerated by plating serial dilutions of remaining bacteria on 
LB agar followed by colony counts 24-48 hours later.  Statistical differences were assessed by 
one-way ANOVA, a > b > c, P < 0.05.  A similar result was shown when this experiment was 
repeated using a higher ceftazidime pre-treatment (75 ng/ml) and subsequent 2 hour treatment 
with LL-37 (15 µg/ml). 
 
We finally showed synergistic killing between LL-37 and ceftazidime when bacteria were first 
treated with LL-37 in a low-salt media followed shortly after by ceftazidime treatment in a 
nutrient-rich broth (Figure A4).  Since these conditions seemed contrived and unlikely to be 
present during immuno-antimicrobial synergy in our infected macrophages, we abandoned LL-




 ROS may synergize with ceftazidime to inhibit bacterial growth but not to kill 
bacteria.  We next turned to another potential mediator of the immuno-antimicrobial synergy 
which is also increased by IFN-γ stimulation of macrophages---ROS (35-38).  Since H2O2 is 
thought to be one of the more stable forms of ROS (39) and is easily added to experiments in 
vitro, we conducted a bacteria killing assay with Burkholderia treated with either ceftazidime, 
H2O2, or the combination of both treatments.  Our first attempts at this experiment showed 
conflicting results.  Occasionally the drugs would interact and result in synergistic inhibition of 
growth, while other times, the effects were only additive and there was no apparent drug 
interaction.  Increasing the sample size to eight replicates, we found that ceftazidime and H2O2 
did show synergistic inhibition of growth (Figure 3.6).  Pooling the data from seven independent 
experiments also showed a synergistic effect at growth inhibition.  We further showed a time 
course of the growth inhibition over the assay length (Figure A5).  We were still skeptical that 
the interaction between ceftazidime and H2O2 was actually synergistic, since it seemed that the 
assay was extremely sensitive. Furthermore, the assay was particularly sensitive to the exact 
concentration of treatments used which may indicate that the conditions for synergistic inhibition 
of growth between H2O2 and ceftazidime are not likely present in our macrophages during 
immuno-antimicrobial synergy.  We did uniquely find that H2O2 strongly synergized with 
gentamicin to inhibit bacterial growth (Figure 3.7).  Since we had been using subinhibitory doses 
of both ceftazidime and H2O2, we were next curious if there would be a synergistic nteraction to 
kill bacteria if we used higher, bactericidal concetrations of both compounds.  In a modified 
bacteria killing assay, we found that bactericidal concentrations of both ceftazidime and H2O2  
were unable to interact to enhance killing (Figure A6).   
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Figure 3.6:  H2O2 and ceftazidime synergistically inhibit growth of Burkholderia.  B. 
thailandensis was grown to mid-log phase and then plated into 96-well plates at an initial density 
of 1x106 CFU/ml.  Ceftazidime (750 ng/ml), H2O2 (20 µM), or the combination of both 
treatments were added to wells with bacteria so that the total volume was 200 µl per well in TSB.  
Plates were incubated for 6 hours at 37°C and then serial dilutions were plated to enumerate 
surviving bacteria.  Statistical differences were assessed by one-way ANOVA, a > b > c > d, P < 
0.05 and statistical synergy was assessed by two-way ANOVA, *P < 0.05.  Data is similar in 
trend to over six independent experiments. 
 
Taken together these results show that the mechanism of immuno-antimicrobial synergy is not 
likely due to H2O2 enhancement of antibiotic-mediated growth-inhibition or antibiotic killing. 
 
 Ferrous sulfate interferes with growth inhibition of ceftazidime and H2O2.  After 
eliminating a few potential mediators of the immuno-antimicrobial synergy, in particular IFN-γ 
induced mediators, we began to think more about the role of ceftazidime in the synergy. 
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Figure 3.7:  H2O2 and gentamicin synergistically inhibit growth of Burkholderia.  B. 
thailandensis was grown to mid-log phase and then plated into 96-well plates at an initial density 
of 1x106 CFU/ml.  Gentamicin (100 µg/ml), H2O2 (20 µM), or the combination of both 
treatments were added to wells with bacteria so that the total volume was 200 µl per well.  Plates 
were incubated for 6 hours at 37°C and then serial dilutions were plated to enumerate surviving 
bacteria.  Statistical differences were assessed by one-way ANOVA, a > b > c > d, P < 0.05 and 
statistical synergy was assessed by two-way ANOVA, *P < 0.05.  Data is representative of three 
independent experiments with treatment groups run in duplicate or triplicate. 
 
We learned about the ongoing debate over whether or not all bactericidal antibiotics kill through 
ROS-mediated pathways.  At the time several studies had contributed evidence to suggest that 
antibiotics may kill bacteria through ROS induced damage (40-42).  If ceftazidime was killing 
bacteria through ROS-mediated pathways, could this be a mechanism by which it could 
synergize with IFN-γ induced ROS?  Perhaps there was a threshold of ROS necessary before 
bacteria would die from ROS-induced damage.  Perhaps ceftazidime and IFN-γ both contributed 
to increase ROS and perhaps increasing ROS could increase the synergistic control of bacterial 
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burden seen inside infected macrophages.  We therefor  added ferrous sulfate to our bacteria 
killing assay as a form of extra iron.  If ceftazidime killed bacteria through a ROS-mediated 
pathway, then increasing free iron availability should increase production of the deadly hydroxyl 
radicals and enhance antibiotic killing.  On the contrary, we found that ferrous sulfate addition to 
the bacteria killing assay interfered with the growth inhibition effects of both ceftazidime and 
H2O2 individually as well as their combination (Figure A7).  After this result, we realized a flaw 
in our experiment.  Our assay with ceftazidime and H2O2 was only inhibiting growth of 
Burkholderia, therefore even if ROS was produced as a mechanism of ceftazidime killing, it was 
not produced in sufficient quantity in our assay to actually kill bacteria.  Therefore, addition of 
extra free iron in the form of ferrous sulfate would not be expected to increase killing, again, 
since there was no killing in our assay, only growth inhibition.  We proposed that ferrous sulfate 
may have instead provided the bacteria with the essntial nutrient, iron, stimulating increased 
growth and replication and leading to the increased bacteria burden in wells with increased 
addition of iron.  Conversely, ferrous sulfate may h ve directly reacted with ceftazidime or H2O2, 
thereby modifying the compounds and inactivating them.  Further studies would need to be 
conducted with bactericidal concentrations of ceftazidime and H2O2 in order to determine if 
ferrous sulfate could increase ROS-mediated bacteri killing.  Instead, with our original question 
unanswered, we turned to flow cytometry to directly determine if ceftazidime induced ROS in 
bacteria. 
 
 Ceftazidime induces ROS production in Burkholderia.  We used flow cytometry in 
order to directly detect an increase in intracellular ROS production due to ceftazidime treatment 
of Burkholderia.  The cell-permeable reagent, HPF, reacts with higly reactive oxygen species 
 
such as hydroxyl radicals to form a 
ceftazidime, HPF was added to cultures and fluorescence was detected using flow cytometry.  
We found that ceftazidime increased the HPF signal inside bacteria compared to untreated 
controls, with about 30% of ceftazidime treated bacteria staining positive for HPF (Figure 3.
This result suggested that ceftazidime did induce ROS production in bacteria and supported a 
role for ROS in the mechanism of antibiotic mediated killing.
Figure 3.8:  Ceftazidime induces ROS production in 
treated with 10 µg/ml ceftazidime for 2 hours (blue line) and subsequently stained with HPF to 
identify levels of ROS compared to an untreated control (re
least two independent experiments.
 
A problem was encountered when we began to look at filamentous 
bacteria were typically formed due to low
However, even at 10 µg/ml we observed filamentous bacteria at short timeperiods of 2
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fluorescent compound (43).  After treating bacteria with 
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of antibiotic treatment.  We observed that longer filaments contained more HPF signal signifying 
increased ROS production.  However, we could never rul  out the possibility that longer 
filaments contained more ROS per cell simply because each cell was increased in length.  It is 
possible that filaments contained the same proportions of ROS as non-filaments.  Therefore we 
could never determine if increased HPF signal necessarily correlated with increased likelihood of 
cell death.  Another study has recently shown that increased HPF signal does not correlate with 
increased likelihood of cell death and also that HPF could react with other cell contents besides 
ROS (44, 45).  Therefore, the use of HPF as an indicator of ROS has been challenged leading us 
to question our experimental results with HPF.  Furthermore, more recent studies have suggested 
that antibiotics do not kill through oxidative damage (44-46).  We therefo abandoned studies 
using HPF to analyze oxidative damage in ceftazidime treated bacteria, and moved on to the 
studies presented in chapter 4. 
 
DISCUSSION 
 In this chapter we discuss several potential mediators of immuno-antimicrobial synergy 
between ceftazidime and IFN-γ.  We first thought that AMPs, namely CXCL10 or LL-37, may 
interact with ceftazidime in cells to synergistically decrease overall intracellular bacterial burden.  
We first showed that IFN-γ but not components of bacteria could stimulate increased production 
of CXCL10 from macrophages.  We then showed that CXCL10 was increased over time during 
our macrophage infection assay due to IFN-γ stimulation of macrophages.  However, we found 
that CXCL10 was not necessary for the immuno-antimicrobial synergy when ceftazidime and 
IFN-γ still interacted to synergistically reduce intracellular bacteria burden in infected CXCL10-/- 
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bone marrow macrophages.  This result suggested that CXCL10 was not a major mechanism of 
immuno-antimicrobial synergy. 
 We then turned our attention to AMP LL-37.  We hypothesized that LL-37 may enhance 
ceftazidime killing of bacteria either through increased permeability or through additional insult 
to the outer membrane or cell wall of the bacteria.  Since Burkholderia is resistant to several 
AMPs (6), our initial experiments focused on E. coli in order to determine whether or not the two 
compounds could interact and kill susceptible bacteria.  Our major finding using E. coli was that 
the order of addition of LL-37 and ceftazidime to bacteria impacted their abilities to kill.  We 
found that when the two compounds were added simultaneously in the bacteria killing assay, 
they showed additive inhibition of growth.  On the contrary, pre-treatment of bacteria with one 
compound resulted in subsequent resistance to the growth inhibition effects of the second 
compound.  Although we did not delve into the mechanism of this surprising effect, we may 
speculate that some sort of compensatory mechanism was induced after injury from the first 
compound which then protected against the effects of the second compound.  Further studies 
would need to be conducted to understand this effect and it would be important to determine 
whether this phenomenon is observed with higher, bactericidal concentrations of both 
compounds as well.   
 When we switched to a bacteria killing assay with Burkholderia, we only observed 
synergistic inhibition of growth with LL-37 and ceftazidime under very specific, contrived media 
and timing parameters.  Since these conditions are unlikely to occur in the macrophages in our 
macrophage infection assay, we abandoned LL-37 as a major mediator of the immuno-
antimicrobial synergy.   
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 Since IFN-γ stimulation of macrophages is known to increase expression of NADPH 
phagocyte oxidase subunits and subsequently increase intracellular ROS production (35-38), we 
thought that H2O2, one of the more stable forms of ROS (39) may be abl  to synergize with 
ceftazidime to kill intracellular bacteria.  In a bcteria killing assay we showed that at 
subinhibitory concentrations of ceftazidime and H2O2, these two compounds could 
synergistically inhibit bacterial growth.  However this result was extremely sensitive to the 
specific concentrations used and was only partially repeatable.  We therefore moved on to look at 
the interaction of higher, bactericidal concentrations of ceftazidime and H2O2 on bacteria killing 
and found that there was no synergistic interaction between these compounds to kill 
Burkholderia at short time points. 
 Around this time in the project we learned about the controversy of whether or not 
antibiotics kill through ROS-mediated pathways.  Weimagined that if ceftazidime was killing 
Burkholderia through a ROS-mediated pathway, perhaps we could target this pathway to 
increase ROS due to both ceftazidime and IFN-γ induced ROS and therefore increase killing of 
bacteria.  We first tested if ceftazidime was ROS-mediated by adding free iron in the form of 
ferrous sulfate to the bacteria killing assay.  In cells superoxide can react with iron-sulfur cluster 
to release free ferrous iron which then reacts withH2O2 through Fenton chemistry to create 
deadly hydroxyl radicals (47-49).  We hypothesized that adding an extra source of free ferrous 
iron could augment hydroxyl radical production and lead to increased killing of bacteria due to 
ceftazidime treatment.  The concentration of ceftazidime we were using was sub-inhibitory, 
which suggested that ceftazidime was not actually killing bacteria.  Therefore, we found that 
ferrous sulfate only protected against growth inhibition and didn’t increase killing since there 
was no killing in the assay even without ferrous sulfate addition.  Further experiments would 
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need to be conducted with higher bactericidal concentrations of ceftazidime in order to determine 
if ferrous sulfate addition could potentiate the killing effect.  Instead, our studies turned to flow 
cytometry to directly measure intracellular ROS in bacteria due to ceftazidime treatment.  We 
used flow cytometry to show that ceftazidime did increase HPF signal in bacteria, however we 
later learned that HPF is not a suitable compound for quantization of intracellular ROS (44, 45).  
Furthermore, recent studies show strong evidence that antibiotics do not kill by a common 
mechanism of ROS induced death (44-46).  Therefore we abandoned studies aimed at 
quantization of ROS induction due to ceftazidime. 
 The mixture of studies presented in this chapter provides the framework for the next two 
chapters.  The purpose of this chapter was to show some of the previous studies aimed at 
understanding the mechanism of immuno-antimicrobial therapy and potential mediators of the 
synergy between ceftazidime and IFN-γ.  Many of the experiments presented here were 
conducted as initial studies, and as such, may not have been followed up by more in-depth 
experiments.  In some cases there may not have seemed a logical flow from one experiment to 
the next, though we have tried to rationalize the progression presented here, however we 
believed these results may be of benefit to future sci ntists.  We hope that some of our negative 
data and failed attempts to identify the mediator of immuno-antimicrobial synergy may provide 
some valuable information to future scientists and possibly save them some time and frustration 
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CHAPTER 4:  INTERACTION OF IFN-γ INDUCED REACTIVE 
OXYGEN SPECIES WITH CEFTAZIDIME LEADS TO 
SYNERGISTIC KILLING OF INTRACELLULAR BURKHOLDERIA 
 
SUMMARY 
 Burkholderia pseudomallei, a facultative intracellular pathogen, causes severe infections 
and is inherently refractory to many antibiotics.  Previous studies have shown that IFN-γ 
interacts synergistically with the antibiotic ceftazidime to kill bacteria in infected macrophages.  
The present study aimed to identify the underlying mechanism of that interaction.  We first 
showed that blocking ROS pathways reversed IFN-γ and ceftazidime mediated killing.  Through 
flow cytometry we observed that IFN-γ, but not ceftazidime, induced significant ROS responses 
in infected macrophages, which led to the hypothesis that synergistic killing of intracellular 
Burkholderia was mediated by the interaction of ceftazidime with IFN-γ induction of ROS.  
Consistent with our hypothesis, we also observed that BSO, another inducer of ROS, could 
substitute for IFN-γ to similarly potentiate the effect of ceftazidime on intracellular killing.  To 
investigate the exact role of ROS responses, we used microscopy to analyze the effect of IFN-γ 
stimulation on intracellular Burkholderia and observed both a lack of vacuolar escape and a lack 
of actin polymerization compared to controls.  These ffects were recapitulated using BSO in 
place of IFN-γ which supports the role of ROS involvement.  Based upon these results, we 
propose a model by which IFN-γ induced ROS responses interact with ceftazidime to 
synergistically kill intracellular bacteria.  Prevention of actin polymerization and vacuolar escape 
due to IFN-γ induced ROS may be a mechanism for increased phagolysos mal killing of 
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intracellular Burkholderia.  Our findings suggest an alternative means of enhancing antibiotic 
activity against Burkholderia through combination with drugs that induce ROS pathw ys. 
 
INTRODUCTION 
 B. pseudomallei, the causative agent of melioidosis, is a gram negative, facultative 
intracellular pathogen that causes potentially lethal acute infections and occasionally chronic 
systemic infections in humans and animals (1-3).  B. pseudomallei can invade and thrive inside 
professional phagocytes and non-phagocytic cells alike (4-6) and the stages of its intracellular 
pathogenesis are well defined (7-9).  After uptake into a cell, Burkholderia escape from the 
phagosome into the cytoplasm where they replicate, polymerize host-cell actin, and spread to 
neighboring cells usually causing cell fusion and MNGC formation (5, 9-13). 
 Treatment of B. pseudomallei infection currently involves in-hospital administration of 
intravenous antibiotics followed by a lengthy eradic tion phase with oral antibiotics (2, 3, 14).  
With such an invasive and expensive treatment regimn there is a greater chance of non-
compliance which can lead to persistent infection.  Therefore, there is a need to identify new 
treatments which may make treatment administration m re practical in areas where access to 
healthcare may be limited.  Therapies which could potentially accelerate the time to recovery or 
decrease the length or dose of intravenous antibiotics could be good candidates for new 
treatments against melioidosis. 
 Although current melioidosis treatments rely exclusively on antibiotics and 
antimicrobials, much research has focused on understanding and characterizing the natural host 
immune responses to B. pseudomallei infection, specifically in regards to the effects of IFN-γ.  
Studies show that IFN-γ is absolutely necessary for protection against acute disease (15-17).  
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There is also a known role for ROS responses due to IFN-γ stimulation in controlling early 
infection with Burkholderia (16, 18).  While the effects of IFN-γ on infected macrophages have 
been studied in great detail, there are few studies that look at the combination of immune 
stimulation with antibiotic treatment, even though this scenario is realistically encountered in 
patients treated for melioidosis.  Our lab has studied these immuno-antimicrobial interactions 
and has previously shown that treatment with IFN-γ can synergistically enhance the effect of 
ceftazidime treatment on infected macrophages, reducing intracellular bacterial burden beyond 
either drug alone (19).  For the following study we used a combination of in vitro and in vivo 
techniques to investigate the underlying mechanism of the interaction between IFN-γ and 
ceftazidime.  From these studies we developed a new model by which IFN-γ induces host 
antimicrobial pathways which synergize with antibiotics to kill intracellular pathogens. 
 
MATERIALS AND METHODS 
Biochemicals. 
 Ceftazidime hydrate, N-acetyl-L-cysteine (NAC), reduced L-glutathione (GSH), L-
Buthionine-sulfoximine (BSO) were purchased from Sigma-Aldrich (St. Louis, MO).  Other 
reagents included recombinant murine IFN-γ  (Peprotech, Rocky Hill, NJ), ketamine (Fort Dodge 
Animal Health, Overland Park, KS), and xylazine (Ben Venue Labs, Bedford, OH).  For flow 
cytometry and fluorescent microscopy, we purchased th  following biochemicals from Life 
Technologies (Carlsbad, CA):  Alexa Fluor 488 conjugated phalloidin, ProLong Gold Anti-fade 
mounting media with DAPI, Di(Acetoxymethyl Ester) (6-Carboxy-2',7'-
Dichlorodihydrofluorescein Diacetate)(carboxy-H2DCFDA), monochlorobimane (mBCl), Alexa 
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Fluor 488 streptavidin-conjugated antibody, and trypsin with EDTA.  Other reagents included 
lysosome-associated membrane protein (LAMP) antibody (ebioscience, San Diego, CA), Alexa 
Fluor 647 conjugated anti-mouse CD11b antibody (BD Biosciences Pharmingen, San Jose, CA), 
rabbit polyclonal anti-B. pseudomallei antibody (provided by D. Waag from USAMRIID), and 
goat anti-rabbit secondary IgG antibody conjugated to Cy3 (Jackson ImmunoResearch Labs, 
West Grove, PA). 
 
Bacteria.   
 B. thailandensis E264 and B. pseudomallei 1026b strains were used for these studies (20, 
21).  Both strains were grown in Luria-Bertaini broth at 37°C with rotary shaking for 16 hours, 
and then stored at -80°C with 15% glycerol until need d.  Frozen vials of bacteria were thawed 
and diluted immediately prior to their use. 
 
Cell lines.   
 RAW 264.7 and J774A.1 macrophage cell lines and murine fibroblast cell line L929 were 
purchased from American Type Tissue Collection (Manassas, VA).  Cell lines were maintained 
in complete media consisting of minimum essential media (MEM; Life Technologies) 
supplemented with 10% fetal bovine serum (FBS) (Atlas, Fort Collins, CO), 0.075% sodium 
bicarbonate (Acros organics, NJ), 1x nonessential amino acids, 0.5x essential amino acids (Life 
Technologies), and 2 mM L-glutamine (Sigma-Aldrich).  Antibiotic additions of 100 Units/ml 
Penicillin and 100 µg/ml Streptomycin (Life Technologies) were added to media for 
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maintenance of cell lines but all experiments were conducted in antibiotic-free media.  All cells 
were maintained at 37°C with 5% CO2. 
 
Mice. 
 Female BALB/c, C57BL/6 and ICR mice were used for these studies. The BALB/c and 
C57BL/6 mice were purchased from Jackson Laboratories (Bar Harbor, ME). The ICR mice 
were purchased from Harlan Laboratories (Indianapolis, IN). All mice were between 6 to 12 
weeks old at the time of their use and were housed nder pathogen-free conditions. All animal 
studies were approved by the Institutional Animal Cre and Use Committee at Colorado State 
University. 
 
Primary bone marrow macrophage culture. 
 Bone marrow macrophages were generated as previously de cribed (22).  Femurs and 
tibias were aseptically removed from mice, transferred to 50 ml conical tubes containing Hank’s 
buffered salt solution (HBSS) supplemented with 2% FBS, and kept on ice.  In a biosafety 
cabinet, bones were cleaned of tissue and bone marrow was flushed from the bones using needles 
and syringes filled with HBSS and supplemented with 2% FBS.  Bone marrow was gently 
resuspended with gentle pipetting and passed throug a 70 µm nylon filter (BD Biosciences 
Pharmingen, San Jose, CA).  Cells were centrifuged at 1200 rpm for 5 minutes at 4°C.  Then 
supernatant was removed and red blood cells were lysed using 2 ml of ammonium-chloride-
potassium (ACK) lysis buffer for 5 minutes, followed immediately by 20 mls of complete MEM 
with antibiotics and 10% L929-conditioned supernatats to dilute the lysis buffer.  Cells were 
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again spun at 1200 rpm for 5 minutes at 4°C.  Remaining white blood cells were plated in 24-
well plates at a concentration of 2 x 106 cells/ml in complete MEM.  Cells were allowed to 
adhere to 24-well plates for 3 hours at 37°C and 5% CO2 after which, non-adhered cells were 
washed away three times with room-temperature HBSS supplemented with 2% FBS.  Complete 
media with antibiotics and 10% L929 conditioned media was reapplied to the cells and plates 
were returned to the incubator.  Addition of 10% L929-conditioned media provided necessary 
growth factors for differentiation of bone marrow myeloid progenitor cells into the 
macrophage/monocyte lineage to enrich for these cells.  Adherent cells were incubated at 37oC 
and 5% CO2 until macrophages reached moderate confluency in wells (approximately 8-12 
days). 
 
Macrophage infection assay.  
 Macrophages were infected and treated as previously de cribed (19).  Briefly, 
macrophages were seeded into 24-well plates with complete MEM (see above) and allowed to 
adhere overnight.  After a 1ml wash with phosphate buffered saline (PBS), B. thailandensis was 
added to macrophages at a multiplicity of infection of 5 and incubated for 1 hour at 37°C in 5% 
CO2.  Aminoglycosides are not considered to penetrate mammalian cells in short time periods 
(23), so macrophages were exposed to high-dose kanamycin-sulfate (350 µg/ml) for 1 hour to 
kill extracellular bacteria.  After two 2 ml washes with PBS to remove kanamycin and dead 
bacteria, treatments were diluted in MEM, applied to macrophages, and incubated for 18 hours.  
Treatments consisted of individual drugs or combinatio s of the following:  ceftazidime (10 
µg/ml), IFN-γ (10 ng/ml), NAC (25, 50, 100 mM), GSH (10, 25, 50 mM), or BSO (5 mM).  
Because the effect of BSO is to deplete GSH by preventing its biosynthesis, BSO treatment was 
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applied as an 18-24 hour pre-treatment of uninfected macrophages prior to the start of the 
macrophage infection assay in order to effectively deplete GSH.  BSO was also added at the 
same concentration with the other treatments for the 18 hours post-infection treatment.  Although 
ceftazidime was applied at 10 µg/ml to infected macrophage cell lines, it was applied at 3 µg/ml 
to infected bone marrow macrophages because 10 µg/ml had too great of an effect at controlling 
intracellular bacterial burden on its own, and therefore made it harder to determine synergy with 
IFN-γ.  After the 18 hour treatment of infected macrophages, extracellular bacteria were washed 
off three times with 2 mls of PBS and macrophages wre lysed with 1 ml of sterile distilled 
water.  Intracellular bacterial burden was then asses ed by plating serial dilutions of the lysates 
on LB agar followed by colony counts 24-48 hrs after plating. 
 
Fluorescent microscopy. 
 RAW 264.7 macrophages were seeded into chamber slids, infected, and treated as 
previously described for the macrophage infection assay.  At indicated times, chamber slides 
containing B. thailandensis infected macrophages were fixed with a solution of 2% 
paraformaldehyde in PBS for 20 minutes, and subsequently permeabilized with 1 ml of 0.1% 
triton-X in PBS for 5 minutes.  Cells were then incubated overnight at 4°C with Alexa Fluor 647 
conjugated anti-mouse CD11b antibody and rabbit ant-Burkholderia serum.  The next morning, 
a blocking buffer consisting of 0.5% bovine serum albumin in PBS was applied to wells for 30 
minutes at room temperature.  For experiments including LAMP staining, the blocking buffer 
used was 5% Donkey serum in PBS with 0.05% Tween applied to wells for 1 hour at room 
temperature.  When LAMP staining was necessary, wells ere also blocked with streptavidin 
(Vector Laboratories, Burlingame, CA) for 15 minutes followed by biotin (Vector Laboratories) 
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for 15 minutes at room temperature.  Phalloidin wasadded to wells at 5 units/well in PBS for 30 
minutes to stain actin filaments.  Lysosome compartments were identified by incubation for 1 
hour with a 1/400 dilution of a biotinylated anti-mouse LAMP antibody followed by a 1/500 
dilution of Alexa Fluor 488 or Alexa Fluor 647 streptavidin-conjugated antibody for 1 hour.  To 
identify Burkholderia, we applied a 1/1000 dilution of a goat anti-rabbit IgG antibody conjugated 
to Cy3.  This secondary antibody was applied with the secondary antibody for LAMP 
identification.  Wells were washed between steps with either 0.5% bovine serum albumin in PBS 
or PBS with 0.05% Tween (for experiments involving LAMP staining).  Coverslips were applied 
with mounting media containing DAPI to stain nuclei.  Images were acquired with a Leica DM 
4500B microscope (Leica Microsystems, Buffalo Grove, IL) fitted with a Retiga 2000R camera 
(QImaging, Surrey, BC, Canada) and using QCapture Pro software (QImaging).  Adobe 
Photoshop CS3 version 10.0.1 (Adobe, San Jose, CA) was used to create color overlay images as 
well as make global manipulations to the linear parameters of black-point and individual color 
brightness for each experiment. 
 
Flow cytometry. 
 Macrophages were treated in 24-well plates at a density of 4x105 cells/ml.  Treatments 
included ceftazidime (10 µg/ml), IFN-γ (10 ng/ml), NAC (20 mM), or BSO (5 mM).  
Macrophages were pre-treated with BSO (5 mM) 18-24 hours prior to infection as well as 18-24 
hours post infection.  After indicated treatment times the cells were washed with PBS and 
detached with 0.25% trypsin with EDTA.  We made several attempts to use the reagent 
hydroxyphenyl fluorescein (HPF, Life Technologies) to detect intracellular ROS in mammalian 
cells, however our negative controls were always positive for the HPF stain.  Therefore we 
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turned to carboxy-H2DCFDA to measure intracellular ROS instead.  Cells were incubated with 
either 5 µM carboxy-H2DCFDA for 30 min at 37oC  to detect total intracellular ROS or with 40 
µM mBCl for 20 minutes at room temperature in the dark, s previously done (24).  The reagent 
mBCl is used to detect intracellular thiols, of which GSH is the most abundant.  Data was 
collected on greater than 50,000 cells per sample using a Gallios Flow Cytometer (Beckman 
Coulter, Brea, CA) and analyzed using FlowJo software version 7.6.5 (Tree Star, Ashland, OR). 
 
In vivo challenge model. 
 BALB/c mice were anesthetized with 100 mg/kg ketamine plus 10 mg/kg xylazine 
administered intraperitoneally.  The B. pseudomallei challenge dose was thawed from a frozen 
stock, diluted in PBS, and delivered intranasally in a volume of 20 µl for a total of 5.7 X 103 
CFU/mouse.  This dose was determined retrospectively by serial dilution, plating onto LB agar, 
and counting colonies 24-48 hours later.  Ceftazidime was administered through the 
intraperitoneal route (IP) at 25 mg/kg of body weight 6 hrs after initial infection and 
subsequently every 12 hrs for a total of six treatments total.  BSO was administered IP to mice at 
2 mmol/kg once daily starting the day before infection and continuing through two days after the 
infection.  Mice were monitored twice daily for signs of disease and were euthanized according 
to predetermined humane end points.  All procedures were performed in a biosafety level 3 







 Means, standard error of the mean (SEM), and P-values were determined and plotted 
using Prism software version 5.00 (GraphPad, La Joll , CA).  For comparisons of two groups, a 
two-tailed Student’s t-test was used to determine statistically significant differences.  For 
comparisons of three or more groups the one-way anal sis of variance (ANOVA) was used 
followed by Tukey’s post test for multiple comparison .  Grouped data was analyzed by two-way 
ANOVA and statistical synergy was determined as before (25) from the interaction P-value of a 
two-way ANOVA.  All differences were considered statistically significant for P < 0.05.  In-vivo 
survival rates were plotted by Kaplan-Meier analysis.  To determine statistical differences 
between two survival curves we compared P-values from the log-rank test to the Bonferroni-
corrected threshold for multiple comparisons. 
 
RESULTS 
 IFN-γ combination with ceftazidime significantly reduces intracellular bacteria 
burden in infected macrophages.  Previously, we found that the combination of IFN-γ with 
ceftazidime synergistically reduced intracellular bcterial burden of B. thailandensis-infected 
AMJ macrophages after 18 hours of treatment (19).  We confirmed the IFN-γ and ceftazidime 
synergistic interaction using a different macrophage cell line, RAW 264.7, (Figure 4.1A) as well 
as primary bone marrow macrophages from C57BL/6, BAL /c, and ICR mice (Figure 4.1B-D).  
For each source of macrophage, the combination of IFN-γ plus ceftazidime controlled the 
intracellular bacteria burden by 3-4 Log10 units compared to untreated controls.  Although β-
lactam antibiotics can be unstable in solution, we showed that supernatants from ceftazidime 
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wells were still bactericidal at the end of the 18 hour incubation (K. Mosovsky and S. Dow, 
unpublished data), which confirmed that the activity of ceftazidime was not compromised during 
our experiments due to its instability.  Surprisingly, IFN-γ and ceftazidime combination failed to 
reduce bacterial burden in the murine fibroblast cell line, L929, compared to untreated controls 
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Figure 4.1:  Ceftazidime and IFN-γ induce synergistic killing of intracellular bacteria in 
macrophages. Adherent RAW 264.7 cells (A) or primary bone marrow macrophages from 
C57BL/6 mice (B) BALB/c mice (C) or ICR mice (D) were infected with B. thailandensis and 
treated with ceftazidime (10 µg/ml for RAW 264.7 cells, 3 µg/ml for bone marrow 
macrophages), IFN-γ (10 ng/ml) or the combination of ceftazidime plus IFN-γ for 18 hours.  
Intracellular bacteria were then enumerated by plating macrophage lysates.  Synergistic 
interactions between ceftazidime and IFN-γ were determined by two-way ANOVA (* P < 0.01, 
** P < 0.001, *** P < 0.0001).  Graphs are representative of data from two or more independent 
























Figure 4.2:  Ceftazidime and IFN-γ fail to kill intracellular bacteria in L929 fibrob last cells.  
L929 fibroblast cells were infected with B. thailandensis and treated with ceftazidime (10 
µg/ml), IFN-γ (10 ng/ml), or the combination of ceftazidime plus IFN-γ for 18 hrs.  Intracellular 
bacteria were then enumerated by plating macrophage lysates.  Significant differences were 
determined by one-way ANOVA.  Graph is representative of data from three independent 
experiments with treatment groups run in triplicate. 
 
IFN-γ treatment of L929 cells has been shown to protect c lls from intracellular pathogens (26, 
27), though some properties of IFN-γ activation, such as increased major histocompatibility 
complex, inhibition of cell growth, and clearance of pathogens may be deficient in L929 cells 
(27, 28).  Taken together these results demonstrate th  the interaction between IFN-γ and 
ceftazidime is exhibited by macrophages but not by non-phagocytic cells. 
 
 Inhibitors of ROS pathway reverse synergistic interaction between IFN-γ and 
ceftazidime.  We considered several mechanisms by which IFN-γ, with no direct bactericidal 
effects itself, could trigger the synergistic interaction with ceftazidime.  These included induction 
of nitric oxide, autophagy, increased uptake of ceftazidime, or induction of ROS responses in 
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IFN-γ-stimulated macrophages.  Increased nitric oxide and increased autophagy were eliminated 
as potential mechanisms of synergy after specific inhibitors of these pathways failed to reverse 
the combination therapy synergy (R. Troyer and S. W. Dow, data not shown).  Furthermore, 
direct quantitation of intracellular ceftazidime con entrations showed an average of 0.0272 
µg/ml after ceftazidime treatment, approximately 50 fold below the MIC, with no increased 
uptake of ceftazidime due to IFN-γ stimulation, a similar result to studies by Miyagi et. al. (18).  
We were then left to explore IFN-γ induction of ROS pathways as a mechanism of synerg. 
 We reasoned that if IFN-γ synergizes with ceftazidime through a ROS-mediated pathway, 
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Figure 4.3:  NAC reverses IFN-γ and ceftazidime synergy.  NAC reversed the intracellular 
killing effect of IFN-γ (10 ng/ml) plus ceftazidime (10 µg/ml) combination therapy on B. 
thailandensis-infected macrophages in a dose-dependent manner.  Statistical differences were 
assessed by one-way ANOVA, a > b > c, P < 0.05.  Results are representative of results from at 




NAC, an antioxidant and cysteine precursor for GSH synthesis 
the synergistic killing of the combination therapy in a concen
4.3).  We also observed this effect in 
that NAC was functioning through increased production of GSH, a prominent cellular 
antioxidant and ROS scavenger in macrophages
measured intracellular GSH levels
increased GSH content (Figure 4.4A) and also decreased total ROS levels in IFN
ceftazidime treated macrophages (Figure 4.4B).
     
 Finally, when GSH was substituted for NAC, we observed a similar titratable effect for 
reversing the IFN-γ and ceftazidime synergistic killing of intracellular 
4.5) and B. pseudomallei (data not shown).  Based on these findings, we
Figure 4.4:  NAC increases intracellular GSH and reduces intracellular ROS.
fluorescent intensity of mBCl after treatment of uninfected RAW cells with NAC (20 mM) for 2 
hrs (P = 0.0004) (B) Intracellular ROS levels (as detected by carboxy
264.7 cells after 10 hr treatment with ceftazidime plus IFN
Results are representative of results from at leasttwo independent experiments.
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(29-31) (see Figure 1.3)
tration-dependent manner (Figure 
B. pseudomallei 1026b (data not shown).  We hypothesized 
 (29, 32-38).  To test this hypothesis, we 
 using mBCl and confirmed that treatment with NAC
 
B. thailandensis
 concluded that 
-H2DCFDA)  in RAW 
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inhibitors of ROS pathways can reverse the killing effect of IFN-γ and ceftazidime, which is in 






IFN-γ + ceftazidime - + + + +
















Figure 4.5:  GSH reverses IFN-γ and ceftazidime synergy.  GSH reversed the intracellular 
killing effect of IFN-γ (10 ng/ml) plus ceftazidime (10 µg/ml) combination therapy on B. 
thailandensis-infected macrophages in a dose-dependent manner.  Statistical differences were 
assessed by one-way ANOVA, a > b > c > d, P < 0.05.  Results are representative of results from 
at least two independent experiments. 
 
  
 IFN-γ induces ROS production in macrophages.  We confirmed increased levels of 
intracellular ROS due to IFN-γ stimulation in uninfected macrophages and found that IFN-γ 
increases ROS as early as 6 hrs post-stimulation with increasing levels through 24 hrs (Figure 
4.6A).  Significantly, the time required for the start of ROS induction, 6 hrs, coincides with the 
time it takes for the combination of IFN-γ plus ceftazidime to begin control of intracellular 
bacteria burden as seen in our previous study (19). We also observed increased ROS in bone 
marrow macrophages due to IFN-γ stimulation (E. Silva and S. W. Dow, data not shown).  In 
infected macrophages, IFN-γ but not ceftazidime increased intracellular ROS levels (Figure 
 
4.6B).  Combined, these results indicate that uninfected and infected macrophages increase 
production of ROS due to stimulation with IFN
  Inducers of ROS can interact with ceftazidime to increase killing of 
Burkholderia.  We next argued that if the IFN
drugs that increased ROS should 
Burkholderia.  BSO specifically inhibits the rate
GSH content through prevention of biosynthesis and resulting in increased intracellular ROS as a 
result of decreased antioxidant activity 
Figure 4.6:  Stimulation with IFN
Histogram overlays of ROS responses as measured with carboxy
(A) IFN-γ elicited ROS responses from uninfected RAW 264.7 macrophages starting 6 hrs post
stimulation with a peak response at 24 hrs. (B) RAW 264.7 macrophages were infected with 
thailandensis, treated with IFN-γ (10 






-γ effect is ROS-mediated, then other pro
a so interact with ceftazidime to enhance killing of intracellular
-limiting step in GSH synthesis 
(39-44) (see Figure 4.7).   
-γ induces ROS production in macrophages.
-H2DCFDA by flow cytometry. 










Figure 4.7:  Pathway by which BSO should decrease intracellular GSH 
BSO specifically inhibits the first step in GSH synthesis.  By blocking GSH synthesis, the cell 
will have fewer antioxidants to degrade ROS, and therefore BSO should indirectly increase ROS 
levels in the cell. 
 
BSO was combined with ceftazidime and/or IFN
(Figure 4.8) and the effect on intracellular bacterial burden was assessed
 The combination of BSO with ceftazidime produced the same level of killing inside 
macrophages as the combination of IF
three drugs significantly increased intracellular killing beyond the effect of IFN
ceftazidime alone (Figure 4.8).  We confirmed that treatment with BSO increased levels of ROS 
in B. thailandensis infected macrophages and further increased ROS levels du  to IFN
4.9A).  Analysis of these results corroborates the hypothesis that BSO was acting as a pro
oxidant in our macrophage infection model.  Finally, we showed that treatment with B
decreases intracellular GSH levels as predicted (Figure 4.9B).  These results demonstrate that 
inducers of ROS can both substitute for IFN
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Figure 4.8:  BSO enhances antibiotic killing of intracellular Burkholderia.  RAW 264.7 cells 
were pre-treated with BSO (5 mM) overnight for 18-24 hrs, infected with B. thailandensis, and 
treated with IFN-γ (10 ng/ml), ceftazidime (10 µg/ml), or the combination of IFN-γ plus 
ceftazidime for another 18 hrs, with or without BSO (5 mM).  Significant differences were 
assessed between groups treated with or without BSO by Student’s T-test, *** P < 0.001. 
 
 
    BSO enhances antibiotic-mediated survival of mice challenged with lethal dose of 
B. pseudomallei.  To validate observations made in vitro we evaluated the interaction of BSO 
plus ceftazidime in vivo using an intranasal challeng  model.  Mice treated with the combination 
of BSO plus ceftazidime were completely protected from a lethal challenge with B. pseudomallei 
(Figure 4.10).  This result was consistent with our previous finding that ceftazidime plus IFN-γ 
greatly enhanced protection of mice from a lethal cllenge of B. pseudomallei (19) and strongly 
suggests a role for ROS in enhancing antibiotic therapy in vivo. 
 
Figure 4.9:  BSO induces intracellular ROS
(A) Histogram overlays of intracellular ROS, as measured by carboxy
cytometry, after macrophage infection with 
(5 mM) or the combination of IFN
with BSO (5 mM) overnight for 18
mBCl, after 18 hrs of treatment with 5 mM BSO (** P = 0.0079).  All data are representative
at least two independent experiments.
 
 
Taken together, our in vitro and in vivo 
ROS responses as the mechanism of the interaction between IFN
intracellular control of bacterial burden.  We next investigated the specific mechanisms by which 
the increased ROS could affect bacterial burden.
 
 Burkholderia fail to escape the phagosome and polymerize actin iside IFN
macrophages.  In order to understand how IFN
and increase killing of intracellular bacteria, we turned to fluorescent microscopy.  We revealed a 
failure of Burkholderia to polymerize host cell actin due to IFN
96 
 and decreases intracellular GSH
-H2DCFDA and flow 
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-γ + BSO for 12 hrs.  All BSO groups were also pre
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Figure 4.10:  The combination of BSO with ceftazidime fully protects mice from lethal B. 
pseudomallei infection.  BALB/c mice (n = 5 per group) were challenged with 5.7 X 103 bacteria 
administered intranasally and subsequently treated with IP ceftazidime (25 mg/kg), BSO (2 
mmol/kg), or the combination of both drugs.  Percent survival was tracked over 70 days.  
Statistical significance between survival curves wa assessed by log-rank test and the 
Bonferroni-corrected threshold for multiple comparisons (P < 0.01667). 
 
 This effect was recapitulated with BSO treatment (Figure 4.12) suggesting ROS involvement. 
Since Burkholderia polymerize host cell actin only after vacuolar escape into the cytoplasm (9-
11) (see Figure 1.2), an investigation was prompted to determine whether bacteria inside IFN-γ 
treated macrophages failed to escape the phagosome.  Since the phagolysosome would be the 
only intracellular compartment we would expect to find both LAMP-1 and bacteria (see Figure 
4.13), we used fluorescent microscopy to quantitate the ratio of bacteria inside IFN-γ treated 
macrophages that co-localized with LAMP-1 compared to untreated controls.  Indeed, we found 
that IFN-γ treated macrophages had a higher proportion of bacteri  that colocalized with LAMP-
1 containing vacuoles suggesting that bacteria failed to escape the phagosome in IFN-γ treated 
groups (Figure 4.14 and Figure A8).  This explanation is consistent with the lack of actin tails on 
Burkholderia inside macrophages treated with IFN-γ or BSO. 
 
Figure 4.11:   B. thailandensis fail
RAW cells were infected with B. thailandensis
ng/ml) (B) for 12 hours.  Macrophages were fixed, permeabilized, and stained with phalloidin to 
identify host cell actin (green), DAPI to stain nuclei (blue), and 
followed by secondary antibody 
captured under 100x magnification.  Actin tails arese n as bright green 
bacteria in (A).  Images are representative of datafrom three independent experiments.
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s to form actin tails inside IFN-γ-treated macrophages.
 and left untreated (A) or treated with IFN
anti-Burkholderia
conjugated to Cy3 to stain B. thailandensis (red).  Images were 







Figure 4.12:  B. thailandensis fails to form actin tails inside BSO
RAW 264.7 cells were pre-treated with BSO (5 mM) for 18
before infection with B. thailandensis
Macrophages were then fixed and stained for host cell a tin (green), nucle
thailandensis (red) and images were captured under 40x magnification.  Image is representative 
of data from two independent experiments.
Figure 4.13:  Diagram of LAMP
lysosomes, late endosomes, and phagolysosomes.  Phagolysosomes, therefore, are the only 
compartment in which bacteria should share co
modified from (12). 
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-treated macrophages.
-24 hrs to deplete intracellular ROS 
 and subsequent treatment for 18 hrs BSO (5 mM).  
i (blue), and 
 
 
-1 expression on phagolysosomes.  LAMP-1 is enriched on 





























Figure 4.14:  Burkholderia inside IFN-γ treated macrophages have higher proportion of 
LAMP-1 colocalization than untreated control.  Quantitation of B. thailandensis 
colocalization with LAMP-1 antibody after 8 hr IFN-γ treatment of infected macrophages.  Data 
is represented as the ratio of colocalized bacteria (with LAMP-1) to total bacteria per field of 
view.  Data represents 10 fields of view for each treatment group (P < 0.0001) and results are 
representative of 2 independent experiments. 
 
DISCUSSION 
 We previously described a novel therapeutic approach for melioidosis which combined 
immune stimulation by IFN-γ with the routinely administered antibiotic, ceftazidime, to 
synergistically enhance killing of intracellular Burkholderia (19).  Here we have shown that the 
mechanism of synergy between IFN-γ and ceftazidime is mediated by IFN-γ induced ROS 
responses in infected macrophages.  Evidence of ROS involvement is supported by our 
experiments in which ROS inhibitors reversed the synergistic killing of IFN-γ and ceftazidime 
while inducers of ROS not only potentiated the killing but could completely substitute for IFN-γ 
with equal effect (see Figure 4.15).   
 
 
Figure 4.15:  Diagram of major findings 
blue line underlines our original hypothesis that IFN
to synergistically kill intracellular 
this hypothesis.  We first showed that IFN
macrophages.  We next showed that antioxidants such as NAC and GSH could remove ROS and 
therefore reverse the synergism.  Finally, we showed that BSO could inhibit GSH synthesis, to 
indirectly increase ROS and lead 
 
We further showed evidence that IFN
phagosome and polymerizing host cell actin, two steps which are deemed necessary for 
intracellular replication and cell-
4.16).  In this way IFN-γ may be able to contain bacteria in the toxic environment of the 
phagolysosome where macrophage defenses can more effectiv ly eliminate them, while also 
controlling replication and interc
 However, we cannot exclude the possibility that what we observe to be IFN
of vacuolar escape is simply an increased frequency or speed of phagosome
events that kills Burkholderia before it is
similar phenotype with BSO treatment, which is not known to increase phagosome
fusion events, we believe that the effect is in fact a prevention of vacuolar escape due to ROS.
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related to ROS production and degradation
-γ induced ROS synergizes with ceftazidime 
Burkholderia.  All of our findings in Chapter 4
-γ increases intracellular ROS in infected 
to synergy, even in the absence of IFN-γ. 
-γ induced ROS prevented bacteria from escaping the 
to-cell spread of the infection (5, 9, 10, 45, 46) (see Figure 
ellular spread of bacteria. 
-lysosome fusion 
 capable of escaping the phagosome.  However due to a 
 
.  The 





 Figure 4.16:  Diagram of major findings related to IFN
intracellular lifestyle.   IFN-γ induced ROS was shown to prevent phagolysosomal escp  of 
bacteria due to lack of actin polymerization associated with bacteria in IFN
macrophages, as well as an increased proportion of bacteria co
treated macrophages. 
  
Furthermore, several other studies have shown a role for IFN
macrophages infected with other intracellular bacteria pathogens 
Myers et. al. showed that ROS inhibitors could partially reverse this
consistent with a ROS-mediated mechanism 
established role for IFN-γ induced ROS
 Although we used high concentrations of NAC and GSH to reverse the synergistic effect, 
we do not believe that our concentrations were unreasonably high or physiologically irrelevant.  
Studies using NAC to enhance athletic performance i humans have used NA
150mg/kg (31).  Additionally, NAC has been used in prevention and treatment of a number of 
health related problems at doses of up to 6 grams per day 
highest concentration of 100 mM NAC is likely within the realm of achievable concentrations at 
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-γ interference with 
-γ treated 
-localized with LAMP
-γ prevention of vacuolar escape in 
(47-49).  Similar to our results, 
 IFN-γ effect, which is 
(49).  Taken together, our results support an already 
 to interfere with intracellular pathogen lifestyles.
C infusions up to 
(50).  Therefore, we believe that our 
 
Burkholderia 




least in local environments.  In most cells, GSH can range in concentration from 1-10 mM (36).  
Since we have seen that IFN-γ induces increased ROS production, we believe that 50 mM GSH, 
the highest concentration used in our studies, was a reasonable dose to scavenge and degrade the 
increased ROS produced due to IFN-γ. 
 There is strong evidence that IFN-γ treatment of macrophages can greatly increase killing 
of intracellular B. pseudomallei (51-55), however we show here that IFN-γ, by itself, has a 
negligible role in controlling intracellular bacterial burden.  We believe this discrepancy can be 
easily explained by differences in macrophage infection models, in particular, the relative order 
and timing of IFN-γ stimulation to macrophage infection.  We and others who pre-activate 
macrophages prior to infection have always seen a strong role for IFN-γ to increase antimicrobial 
responses and killing of intracellular bacteria (51-55), whereas the infection model used for the 
current study consisted of macrophage infection followed by activation by IFN-γ.  While pre-
activation with IFN-γ produces a clear advantage to study the specific antimicrobial effects of 
fully activated macrophages, it is likely that pre-activating macrophages in the absence of 
bacteria elicits a different antimicrobial response than macrophages activated in the presence of 
bacteria and IFN-γ (56). 
 We believe our system of infection, in which macrophages are infected and subsequently 
treated with IFN-γ might more closely mimic the timing in a natural infection by which a host is 
infected first and an immune response is mounted second.  However, an obvious disadvantage of 
this infection model is that treatment of infected macrophages with IFN-γ has never elicited a 
strong killing effect on its own which makes it difficult to determine the mechanism behind any 
IFN-γ mediated antimicrobial responses.  Fortunately, our current study focused on the 
mechanism of the combination of IFN-γ with ceftazidime which elicited an effect with large 
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enough magnitude to easily study.  As to why IFN-γ stimulation doesn’t control infection after 
macrophage infection, we suspect that by the time ROS is maximally induced by IFN-γ 
stimulation, the macrophages are already overwhelmed by the infection and so it becomes an 
issue of too little too late.  However, even increased ROS due to BSO depletion of GSH was 
unable to increase IFN-γ stimulated intracellular killing without the presence of ceftazidime, 
which suggests a critical and perhaps underestimated rol  for ceftazidime in our infection model.  
After all, even though we have found IFN-γ induced ROS are an important component of the 
synergistic killing, ceftazidime is a very large component of that synergy that we did not focus 
on in this chapter.  It is important to uncover the sp cific contributions of both ceftazidime and 
IFN-γ to the synergistic interaction and chapter 5 will address these points. 
 In the current study we have shown substantial evidence of a role for IFN-γ induced ROS 
responses to synergize with ceftazidime to control B. pseudomallei infection in macrophages.  
While there is a well documented role for IFN-γ induced RNS responses in the killing of B. 
pseudomallei, typically through induction of inducible nitric oxide synthase (iNOS) (18, 51, 54, 
55, 57), far fewer studies support a role for IFN-γ induced ROS responses.  Although less 
frequently evaluated, ROS responses have been implicated in control of Burkholderia infection 
in the past.  For example, in vivo knock-out studies by Breitbach and colleagues showed that 
NADPH oxidase, but not iNOS, was important for contr lling mortality during acute phase 
infection with B. pseudomallei (16). Furthermore, two studies have shown a role for IFN-γ 
induced ROS response control of bacterial burden during acute phase infection with B.
pseudomallei (16, 18).  Finally, connections between contraction of melioidosis and patients with 
chronic granulomatous disease, who lack a functional NADPH phagocyte oxidase, suggest a role 
for NADPH phagocyte oxidase generated ROS responses i  protection of hosts (58, 59).  While 
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the issue of IFN-γ induced antimicrobial mechanisms is inarguably complex, we believe there 
may be a role for both IFN-γ induced RNS and ROS responses which at least partially depends 
on the current activation state of the host immune cells at the time of initial infection. 
   In conclusion, we have shown that IFN-γ induced ROS can synergize with ceftazidime 
to increase intracellular killing of Burkholderia.  The effect of IFN-γ to keep the bacteria in the 
phagolysosome and prevent their escape into the cytoplasm suggests that IFN-γ may inhibit 
further spread and replication of this intracellular p thogen.  We believe our results show that 
IFN-γ induced ROS is a likely factor involved with preventing escape from the phagolysosome.  
Our results also suggest that pro-oxidant drugs that increase intracellular ROS responses may 
have similar antibiotic enhancing effects.  Continuation of these studies on immuno-
antimicrobial interactions may lead to discovery of alternative therapies for treating melioidosis 
which make use of pro-oxidant, ROS inducing drugs as non-specific enhancers of antibiotic 
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CHAPTER 5:  THE ROLE OF COMPARTMENTALIZED KILLING 





 Burkholderia pseudomallei, the causative agent of melioidosis, is a facultative 
intracellular pathogen of phagocytes and non-phagocytes that causes severe infections in humans 
and animals.  In chapter 4 we showed a role for IFN-γ induced ROS in the interaction of IFN-γ 
and ceftazidime which synergistically kills intracellular Burkholderia.  In the present chapter we 
further extended our investigation into the specific and individual contributions of both IFN-γ 
and ceftazidime to the synergy.  We first used fluorescent microscopy to show that IFN-γ treated 
macrophages appeared to control the intracellular bacterial burden, whereas ceftazidime treated 
macrophages did not.  We therefore hypothesized that ceftazidime primarily controlled 
extracellular bacterial burden and IFN-γ primarily controlled intracellular bacterial burden.  We 
next tracked extracellular numbers of bacteria during our macrophage infection and found a role 
for ceftazidime to control extracellular bacteria, an effect that was synergistically enhanced with 
co-treatment with IFN-γ.  Using a macrophage-free bacteria killing assay we determined that 
ceftazidime alone kills Burkholderia, which meant that IFN-γ activated macrophages, but not 
IFN-γ itself, helps to control extracellular bacterial burden.  We then studied these IFN-γ 
activated macrophages to show their ability to kill intracellular bacteria.  We found no role of 
macrophages pre-treated with ceftazidime to reduce intracellular numbers, suggesting that IFN-γ 
alone controls intracellular bacterial burden.  Taken together, our results suggest that the effects 
112 
 
of IFN-γ and ceftazidime treatment can be simplified to individual compartments, such that IFN-
γ stimulates killing of intracellular Burkholderia and prevents further spread and replication, 
while ceftazidime kills extracellular bacteria, thereby reducing the pool of bacteria that can 
further infect healthy host cells.  In summary, it is only with the combination of intracellular 
killing by IFN-γ induced ROS, and ceftazidime-mediated extracellular ki ling, that we see 
synergistic reductions in bacterial burden in the system as a whole as well as overall maintained 
health of the host cells. 
 
INTRODUCTION 
 B. pseudomallei is a facultative intracellular pathogen and the causative agent of 
melioidosis, a severe and often life-threatening emerging infectious disease (1-3).  B.
pseudomallei is inherently resistant to many classes of antibiotics as well as host-derived 
antimicrobial defenses (4-8).  Suggested treatment of melioidosis includes intravenous 
administration of either ceftazidime or meropenem for two weeks followed by an oral 
eradication therapy of trimethoprim and sulfamethoxazole for an additional three months (6, 9).  
However, even with antibiotic treatment, recurrent infections due to relapse are not uncommon 
(10-12).  Therefore there is a critical need for new therapies which can enhance antibiotic 
efficacy or interfere with Burkholderia pathogenesis. 
 Burkholderia can infect and survive inside both phagocytes and non-phagocytes and its 
specific intracellular lifestyle is well characterized (13, 14).  Burkholderia utilizes host 
microfilaments to facilitate its entry into vacuoles or phagosomes within minutes of contact with 
host cells (15-18).  Bacteria then lyse the vacuole and escape into the host cell cytoplasm where 
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they replicate, polymerize host cell actin, and form MNGCs through induction of cell fusion and 
cell-to-cell spread (7, 15, 18, 19).  Macrophages eventually rupture, releasing bacteria back into 
the extracellular space (15). 
 IFN-γ, which is obligatory for resistance to Burkholderia infection (20-23), has a well 
recognized role for activating macrophages to enhance killing of intracellular Burkholderia 
through either increased ROS or RNS (24, 25).  Studies also show that IFN-γ is capable of 
interfering with the normal intracellular lifestyle of Burkholderia by almost completely 
preventing cell fusion and MNGC formation (26, 27).  In chapter 4 we also showed that IFN-γ 
prevents bacterial escape from the phagolysosome.  Taken together, there is a strong role for 
IFN-γ in the resistance to Burkholderia and control of infection.   
 In a previous study we showed that IFN-γ could interact with ceftazidime to 
synergistically reduce bacterial burden of Burkholderia inside infected macrophage and also 
protect mice from a lethal challenge with B. pseudomallei (28).  Since IFN-γ is not known to 
have antimicrobial effects on its own, we suspected a role for IFN-γ activation of macrophages to 
synergize with ceftazidime.  In chapter 4 we showed that IFN-γ induced ROS contributes to the 
mechanism of synergistic intracellular killing, but the role of ceftazidime in the synergy was still 
unknown.  Here we expand our investigation to the individual contributions of both IFN-γ and 
ceftazidime to the synergistic killing and we further evaluate the role of ROS.  We show that 
while IFN-γ and ceftazidime synergistically interact to reduce bacterial burden intracellularly, 
they also interact to reduce extracellular bacterial burden.  Surprisingly, their effects seem to be 
compartmentalized to either the intracellular or extracellular effects, although killing in one 
compartment does affect the other.  In the end, we propose a new model to describe the 
dynamics of our macrophage infection model which is consistent with our results. 
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MATERIALS AND METHODS 
Biochemicals. 
 Ceftazidime hydrate, N-Acetyl-L-cysteine (NAC), and reduced L-Glutathione (GSH) 
were purchased from Sigma-Aldrich (St. Louis, MO). ther reagents included recombinant 
murine IFN-γ (Peprotech, Rocky Hill, NJ), Alexa Fluor 488 conjugated phalloidin (Life 
Technologies, Carlsbad, CA), ProLong Gold Anti-fade mounting media with DAPI (Life 
Technologies), rabbit polyclonal anti-B. pseudomallei antibody (provided by D. Waag from 
USAMRIID), and goat anti-rabbit secondary IgG antibody conjugated to Cy3 (Jackson 
ImmunoResearch Labs, West Grove, PA). 
 
Bacteria. 
 B. thailandensis E264 was used in all studies (29).  Bacteria were grown in trypticase soy 
broth (BD Biosciences, San Jose, CA) at 37°C with ro ary shaking for 16 hours and stored at -
80°C in 15% glycerol until needed.  Mid-logarithmic phase bacteria were grown for 
approximately 3 hours with rotary shaking from a 1 to 25 dilution of an overnight culture until an 
optical density of 0.5-0.8 was reached. 
 
Cell lines. 
 RAW 264.7 macrophages (ATCC, Manassas, VA) were maintained at 37°C with 5% 
CO2 and used for all studies.  Cell lines were grown and maintained in complete media (cMEM) 
consisting of minimum essential media (MEM; Life Technologies) supplemented with 10% fetal 
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bovine serum (Atlas, Fort Collins, CO), 0.075% sodium bicarbonate (Acros organics, NJ), 0.5x 
essential amino acids, 1x nonessential amino acids (L fe Technologies, Carlsbad, CA), and 2 
mM L-glutamine (Sigma-Aldrich).  Penicillin (100 Units/ml) and Streptomycin (100 µg/ml) 
(Life Technologies) were added to media for maintenance of cell lines but all experiments were 
conducted in antibiotic-free cMEM. 
 
Resting macrophage infection assay. 
 Macrophages were infected and treated as previously de cribed (28).  Briefly, 
macrophages were seeded into 24-well plates with antibiotic-free cMEM and allowed to adhere 
overnight.  Macrophages were infected with B. thailandensis E264 at a multiplicity of infection 
of 5 for 1 hour followed by a 1 ml wash with phosphate buffered saline (PBS).  High dose 
kanamycin monosulfate (Thermo Fisher Scientific, Waltham, MA) was then applied for 1 hour 
to kill extracellular bacteria.  The MIC of kanamycin for B. thailandensis E264 is 128 µg/ml, and 
the concentration used to kill extracellular bacteria in this assay was 350 µg/ml (30).  
Macrophages were then washed twice with 2 mls PBS to remove kanamycin and dead bacteria 
and then incubated with IFN-γ (10 ng/ml), ceftazidime (10 µg/ml), or the combination of both 
treatments in cMEM for 18 hours.  The MIC of ceftazidime for B. thailandensis E264 is 1.75 
µg/ml (31).  After the treatment period, cells were washed three times with 2 mls PBS and lysed 
with 1 ml sterile distilled water.  Intracellular bacterial burden was quantified by plating serial 
dilutions of the lysates on Luria-Bertaini (LB) agar (BD Biosciences) followed by colony counts 
24-48 hours later.  In experiments aimed to determine synergy between IFN-γ and other 
antibiotics, the following antibiotics and concentrations were tested:  piperacillin (10 µg/ml, 100 
µg/ml), imipenem (1 µg/ml, 10 µg/ml), ciprofloxacin (0.1 µg/ml, 0.3 µg/ml), gentamicin (200 
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µg/ml), chloramphenicol (1 µg/ml, 3 µg/ml), doxycycline (1 µg/ml, 3 µg/ml), trimethoprim (0.1 
µg/ml, 1 µg/ml).  Single antibiotic titration studies were conducted on infected macrophages and 
the above antibiotic concentrations were chosen for synergy studies because they had a small or 
negligible effect on reducing intracellular bacterial burden compared to untreated controls.  All 
of the antibiotic concentrations used to determine synergism with IFN-γ had less than a 2 log10 
effect at controlling intracellular bacterial burden on their own.  For experiments that aimed to 
quantitate extracellular bacteria numbers after the 18 hour treatment period, supernatants were 
first gently pipetted up and down to resuspend bacteria in wells without disturbing the adhered 
macrophages.  Then extracellular bacteria were quantitated by plating serial dilutions of the 
supernatants onto LB agar, followed by colony counts 24-48 hours later. 
 
Pre-activated macrophage infection assay. 
 In order to specifically study the intracellular antimicrobial effects of fully activated 
macrophages, we pre-activated adhered macrophages with IFN-γ (10 ng/ml) or pre-treated 
macrophages with ceftazidime (10 µg/ml) for 18 hours prior to infection.  Following the 18 hour 
pre-treatment, macrophages were infected with B. t ailandensis E264 at a multiplicity of 
infection of 5 for 30 minutes.  Since we expected rapid killing of bacteria in IFN-γ pre-activated 
macrophages, the infection time was only 30 minutes (instead of the 1 hour infection we 
typically use for our resting macrophage infection assays) so that we could more quickly observe 
killing effects.  Following the 30 minute infection, macrophages were washed once with 2 mls of 
PBS and high dose kanamycin monosulfate (350 µg/ml) was applied to kill extracellular bacteria 
for 1 hour.  Macrophages were then washed twice with 2 mls of PBS and cMEM was applied to 
the macrophages for up to 6 hours.  In order to ensur  that only pre-treatment effects were 
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evaluated, no treatments were present during the infect on nor the 6 hour assay length.  When 
NAC (50 mM) or GSH (50 mM) were used in the pre-activated macrophage infection assay, 
these additional treatments were added for 3 hours prior to infection and washed off with 1 ml 
PBS prior to the infection.  We used this timing of treatments to ensure that NAC and GSH 
additions would work to decrease the maximal production of ROS due to IFN-γ activation of 
macrophages.  The length of the assay was shortened o 6 hours from the 18 hour resting 
macrophage infection assay because we expected rapid killing of intracellular bacteria.  The use 
of the pre-activated macrophage infection assay helped determine how fully activated 
macrophages might react to intracellular pathogens when there is no lag-time for initiation of 
activation.  Therefore, we used the pre-activated macrophage infection assay to help predict what 
might be occurring in our resting macrophage infection assay after full IFN-γ activation of the 
macrophages. 
 
Extracellular bacteria killing assay. 
 In order to evaluate the effects of the treatments o  bacterial killing alone, we used a 
bacterial killing assay consisting of only bacteria and treatments, and in the complete absence of 
macrophages.  Our goal was to simulate the exact extracellular environment of our resting 
macrophage infection model but in the absence of macrophages.  Therefore we used the same 
treatment concentrations (see below), the same media (cMEM) and volume of media in wells 
(500 µl), and the same incubation conditions and times (see below).  Treatments were pre-
prepared, diluted in cMEM, and added to 24-well plates at a total volume of 100 µl for 
treatments.  Treatments were ceftazidime (10 µg/ml), IFN-γ (10 ng/ml), or GSH (10, 25, 50 mM) 
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or combinations of these treatments.  Meanwhile, B. thailandensis was grown to mid-logarithmic 
phase from an overnight culture, diluted in cMEM, and 400 µls were added to the 24-well plate 
already containing the treatments.  The initial density of bacteria was 1 x 107 CFU/well and a 
total of 500 µl was present in each well.  Plates wre incubated at 37°C with 5% CO2 for 18 
hours to simulate the same incubation conditions as our resting macrophage infection assay.  
After 18 hours, well contents were resuspended by slowly pipetting up and down, and surviving 
bacteria were enumerated by plating serial dilutions f well contents on LB agar and counting 
colonies after 24-48 hours.  
 
Fluorescent microscopy. 
 RAW 264.7 resting macrophages were seeded onto chamber slides, infected and treated 
the same as in the resting macrophage infection assay, and after 12 hours were fixed with a 1 ml 
of a 2% paraformaldehyde solution for 20 minutes at room temperature.  Cells were 
permeabilized with 1 ml of 0.1% triton-X in PBS for 5 minutes and subsequently incubated with 
a 1/15,000 dilution of rabbit anti-Burkholderia serum at 4°C overnight in the dark.  Chamber 
slides were then blocked with a 0.5% solution of bovine serum albumin in PBS for 30 minutes at 
room temperature.  Host cell actin was stained withphalloidin at 5 units/well in PBS for 30 
minutes in the dark, followed by three 10 minute wash steps with PBS.  Then a goat anti-rabbit 
IgG antibody conjugated to Cy3 was diluted 1/1000, added to the chamber slides, and incubated 
for 1 hour in the dark.  After three 3 minute washes with room temperature PBS in the dark, the 
slides were left to dry and then nuclei were stained with 15 µl of DAPI-containing mounting 
media applied with the coverslip.  Images were acquired with a Leica DM 4500B microscope 
(Leica Microsystems, Buffalo Grove, IL) fitted with a Retiga 2000R camera (QImaging, Surrey, 
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BC, Canada) and using QCapture Pro software (QImaging).  Adobe Photoshop CS3 version 
10.0.1 (Adobe, San Jose, CA) was used to create tripl -color overlay images as well as make 
global manipulations to the linear parameters of black-point and individual color brightness for 
each image. 
 
Primary bone marrow macrophage culture. 
 Bone marrow macrophages were generated as previously de cribed (32).  Femurs and 
tibias were aseptically removed from mice, transferred to 50 ml conical tubes containing Hank’s 
buffered salt solution (HBSS) supplemented with 2% FBS, and kept on ice.  In a biosafety 
cabinet, bones were cleaned of tissue and bone marrow was flushed from the bones using needles 
and syringes filled with HBSS and supplemented with 2% FBS.  Bone marrow was gently 
resuspended with gentle pipetting and passed throug a 70 µm nylon filter (BD Biosciences 
Pharmingen, San Jose, CA).  Cells were centrifuged at 1200 rpm for 5 minutes at 4°C.  Then 
supernatant was removed and red blood cells were lysed using 2 ml of ammonium-chloride-
potassium (ACK) lysis buffer for 5 minutes, followed immediately by 20 mls of complete MEM 
with antibiotics and 10% L929-conditioned supernatats to dilute the lysis buffer.  Cells were 
again spun at 1200 rpm for 5 minutes at 4°C.  Remaining white blood cells were plated in 24-
well plates at a concentration of 2 x 106 cells/ml in complete MEM.  Cells were allowed to 
adhere to 24-well plates for 3 hours at 37°C and 5% CO2 after which, non-adhered cells were 
washed away three times with room-temperature HBSS supplemented with 2% FBS.  Complete 
media with antibiotics and 10% L929 conditioned media was reapplied to the cells and plates 
were returned to the incubator.  Addition of 10% L929-conditioned media provided necessary 
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growth factors for differentiation of bone marrow myeloid progenitor cells into the 
macrophage/monocyte lineage.  Adherent cells were incubated at 37oC and 5% CO2 until 
macrophages reached moderate confluency in wells (approximately 8-12 days). 
 
Statistical analyses. 
 Unless otherwise noted, all data is represented by the mean +/- standard error of the mean 
(SEM).  Means, SEM, and P-values were determined and plotted using Prism software version 
5.00 (GraphPad, La Jolla, CA).  A two-tailed Student’s t-test was used to determine statistically 
significant differences between two groups.  For comparisons of three or more groups, the one-
way analysis of variance (ANOVA) was used followed by Tukey’s post test for multiple 
comparisons.  Grouped data was analyzed by two-way ANOVA and statistical synergy was 
determined as before (33) from the interaction P-value of a two-way ANOVA.  The term synergy 
describes an interaction between two drugs which is greater than either drug alone or the additive 
effects of the drugs combined.  It is determined stati tically by comparing the untreated group, 
both single treatment groups, and the combination treatment group.  All differences were 
considered statistically significant for P < 0.05. 
 
RESULTS 
 IFN-γ synergizes with other bactericidal antibiotics to kill intracellular 
Burkholderia.  Our previous investigations of immuno-antimicrobial therapy have focused 
solely on the ability of the antibiotic ceftazidime to synergize with IFN-γ (28).  We explored 
121 
 
interactions between IFN-γ and other antibiotics in our macrophage infection model and found a 
surprising ability of sub-therapeutic bactericidal but not bacteriostatic antibiotics to similarly 
synergize with IFN-γ to reduce intracellular bacterial burden (R. Troye and S. Dow, data 
unpublished).  Furthermore, the synergistic effect with IFN-γ broadly encompassed several 
classes of bactericidal antibiotics including cephalosporins, penicillins, carbapenems, 
fluoroquinolones, and aminoglycosides, many of which B. pseudomallei are resistant to alone 
(results summarized in Table 5.1).  We also observed immuno-antimicrobial synergy in 
macrophages infected with E. coli (A. Melia, K. Mosovsky, and S. Dow, data not shown).  These 
results imply that immuno-antimicrobial synergy betw en IFN-γ and antibiotics is widely 
observed over several classes of bactericidal antibiotics and may be relevant to other Gram 
negative intracellular pathogens. 
       Table 5.1:  IFN-γ synergizes with bactericidal antibiotics. 
 
Antibiotic Drug Class Static/Cidal Synergy?
Ceftazidime Cephalosporin Cidal Yes
Piperacillin Penicillin Cidal Yes
Imipenem Carbapenem Cidal Yes
Ciprofloxacin Fluoroquinolone Cidal Yes
Gentamicin Aminoglycoside Cidal Yes
Chloramphenicol Phenicol Static No
Doxycycline Tetracycline Static No
Trimethoprim DHFR inhibitor Static No  
 
  
 Ceftazidime does not control intracellular replication of Burkholderia.    Previous 
studies had shown that IFN-γ played a major role in controlling intracellular replication of 
Burkholderia.  Microscopy of RAW 264.7 infected cells visually confirmed that these IFN-γ 
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effects were reproduced with its combination with ceftazidime, but not by ceftazidime alone 
(Figure 5.1).  Untreated macrophages formed large multinucleated giant cells (MNGC), with 
large hubs of densely replicating bacteria.  Bacteria around the edges of the MNGC had 
polymerized actin tails, signifying their attempt to spread to neighboring cells.  The macrophages 
and bacteria in the ceftazidime-treated group looked very similar, however, any group treated 
with IFN-γ appeared much different.  We confirmed the lack of actin polymerization in IFN-γ 
treated cells that we had seen before, and also observed a lack of MNGC from both IFN-γ treated 
groups.  It appeared that without MNGC formation, IFN-γ treated macrophages appeared to have 
been able to control the intracellular infection much better than untreated controls or ceftazidime 
treatment (Figure 5.1).  Noting the similarities of appearance between ceftazidime and untreated 
controls, we hypothesized that the main contribution of ceftazidime to the synergism must be 
entirely through extracellular killing, while the role of IFN-γ may be more focused on 
intracellular control of bacterial burden.  We first conducted experiments to determine the 
specific contribution of ceftazidime extracellular control of bacterial burden. 
 
 Ceftazidime primarily controls extracellular bacterial burden.  We first analyzed the 
ability of ceftazidime to control extracellular replication of Burkholderia during the macrophage 
infection.  We were surprised to find that ceftazidime appeared to play a role in controlling 
extracellular bacterial burden during macrophage inf ction (Figure 5.2A).  We were also 
surprised to show that while IFN-γ had no effect on extracellular bacterial burden itself, it 
significantly enhanced the ceftazidime effect to contr l extracellular bacteria.  This result 
prompted us to investigate whether IFN-γ increased antibiotic killing or could kill bacteria itself.   
 
Figure 5.1:  IFN-γ alone controls intracellular replication of 
macrophages were infected with 
with (A) no treatment, (B) ceftazidime (10 
of ceftazidime and IFN-γ.  Cells were then 
identify host cell actin (green), DAPI to stain nuclei (blue) and anti
by a secondary antibody conjugated to Cy3 to 
captured at 40x magnification and 
The blue nuclei which are not associated with green actin filaments are thought to be dead or 
dying cells due to B. pseudomallei
precedes cell death (36). 
 
In our extracellular bacteria killing assay we reproduced the same in vitro 
time in a macrophage-free system (see Materials and Methods), and found that ceftazidime alone 
killed B. thailandensis cultures (Figure 
not significantly increase killing due 
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Burkholderia.  RAW 264.7 
B. thailandensis for 1 hr and subsequently treated for 12 hrs 
µg/ml), (C) IFN-γ (10 ng/ml), or (D) the combination 
fixed, permeabilized, and stained with phalloidin to 
-Burkholderia 
identify B. thailandensis (red).  Images 
are representative of at least two independent experiments.
 toxicity (19, 34, 35), since the loss of filamentous actin 
culture conditions, this 
5.2B).  IFN-γ had no bactericidal effects alone and did 




























































Figure 5.2:  Ceftazidime primarily controls extracellular bacterial burden.  (A) RAW 264.7 
cells were infected with B. thailandensis and treated for 24 hours with IFN-γ (10 ng/ml), 
ceftazidime (10 µg/ml), or the combination of ceftazidime and IFN-γ.  During the macrophage 
infection, extracellular bacterial burden was assesed at 0, 6, 10, and 24 hrs post-treatment by 
plating serial dilutions of well supernatants (see Materials and Methods for more details).  
Significant differences were assessed at all time points by two-way repeated measures ANOVA 
and compared to untreated control (*P < 0.05, ***P < 0.001).  (B) B. thailandensis was treated 
with ceftazidime (10 µg/ml), IFN-γ (10ng/ml) or the combination of ceftazidime and IFN-γ for 
18 hours in the absence of macrophages.  Surviving bacteria were enumerated by plating 
dilutions of remaining bacteria after 18 hrs of trea ment.  Significant differences were assessed 
by one-way ANOVA, a > b (P < 0.0001).  Both graphs are representative of two independent 
experiments with treatment groups run in triplicate or quadruplicate. 
 
 
This meant that the IFN-γ enhanced antibiotic effect to reduce extracellular bacterial numbers, 
seen in Figure 5.2A, must have been due to IFN-γ activation of macrophages, and not IFN-γ 
itself.  Taken together these results show that ceftazidime primarily kills extracellular bacteria in 
our macrophage infection model, though IFN-γ activation of macrophages can contribute to 
reduction of extracellular numbers.  We had previously shown that IFN-γ and ceftazidime can 
interact synergistically to control intracellular bacterial burden, but we had also just shown a 




 IFN-γ, but not ceftazidime, kills intracellular Burkholderia and prevents 
intracellular replication.  After showing that ceftazidime primarily controls extracellular 
bacterial burden we began to suspect that the role of IFN-γ and IFN-γ induced ROS may be 
strictly intracellular control of bacteria.  To investigate this hypothesis, we turned to a pre-
activated macrophage infection model to determine the intracellular killing power of 
macrophages fully activated by IFN-γ.  Shortening the assay to 6 hrs instead of 18 hrs enabled us 
to more accurately describe killing in the intracellular compartment without confounding by 
extracellular bacteria.  Macrophages were pre-activted with IFN-γ for 18 hours and then 
infected with B. thailandensis (see Materials and Methods for further details).  Bacteria that had 
been taken up into the intracellular compartment during the initial infection were steadily killed 
over the entire 6 hr assay (Figure 5.3A).  Conversely, Burkholderia actually replicated inside 
untreated macrophages over the 6 hours.  This result clearly showed that IFN-γ activation of 
macrophages could induce killing responses to control intracellular killing and prevent 
replication.  The difference in intracellular bacteria numbers at time T = 0 between untreated and 
pre-activated macrophages was likely due to the 1.5 hour time lapse between the start of 
infection and the start of the 6 hour experiment.  We suspect that Burkholderia invaded untreated 
and pre-activated macrophages equally, but pre-activated macrophages likely began killing 
bacteria immediately after infection and throughout the 1 hour kanamycin step (see Materials 
and Methods), leading to the small, but significant difference in intracellular burden at time  
T = 0.   
 We next evaluated the ability of ceftazidime to contr l intracellular bacterial burden.  
Microscopy images of infected macrophages showed that ceftazidime didn’t appear to play a 














































A BIntracellular Bacterial Burdenin Pre-activated Macrophages
Intracellular Bacterial Burden
in Pre-treated Macrophages (6 hrs)
 
Figure 5.3:  IFN-γ alone kills intracellular bacteria and prevents replication.  (A-B) RAW 
264.7 macrophages were pre-activated with IFN-γ (10 ng/ml) or pre-treated with ceftazidime (10 
µg/ml) for 18 hrs prior to infection with B. thailandensis.  At indicated times lysates were plated 
to enumerate surviving intracellular bacteria.  (A)Time course of intracellular killing due to pre-
activation with IFN-γ prior to infection.  Significant differences compared to untreated control 
were assessed at each time point by two-way ANOVA (***P < 0.001).  (B) Intracellular 
bacterial burden after 6 hours of infection.  Statis ical differences were assessed by one-way 
ANOVA, a > b (***P < 0.0001).  Both graphs are reprsentative of two independent experiments 
run in triplicate or quadruplicate. 
 
Furthermore, we had previously found that whole cell intracellular concentrations of ceftazidime 
(either alone or without IFN-γ stimulation) were more than 50 fold below the MIC of 
ceftazidime (R. Troyer and S. Dow, unpublished data).  However, if ceftazidime was taken up 
into specific compartments, the localized concentration of ceftazidime could be much higher.  To 
determine the contribution of ceftazidime to intracellular killing, we pre-treated macrophages for 
18 hours with IFN-γ (as before), or ceftazidime, or the combination of b th drugs.  We then 
removed all treatments and infected the macrophages with B. thailandensis.  After 6 hours we 
lysed the macrophages and determined surviving bacteri  by plating dilutions of lysates onto LB 
agar.  Only macrophages pre-treated with IFN-γ showed intracellular killing of Burkholderia 
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during the 6 hour assay (Figure 5.3B).  Macrophages pr -treated with ceftazidime were both 
unable to control intracellular bacterial burden and u able to enhance the killing effect seen with 
IFN-γ activation.  These results suggest that over 18 hours ceftazidime is unable to accumulate in 
macrophages to an extent that could reduce bacterial numbers.  Taken together these results 
support a role for IFN-γ but not ceftazidime in contributing to killing in the intracellular 
compartment. 
 
 IFN-γ induced ROS kills intracellular bacteria.  We had now shown a role for 
ceftazidime to kill extracellular bacteria and a role for IFN-γ to kill and prevent replication of 
intracellular bacteria.  However we had not specifically investigated the role for ROS in either of 
these compartments.  In chapter 4 we had shown that IFN-γ induced ROS responses were 
involved in the mechanism of immuno-antimicrobial synergy by showing that antioxidants NAC 
and GSH could reverse the synergistic intracellular killing.  However, now that we had gained an 
appreciation of the role for compartmentalized killing in the immuno-antimicrobial synergy, we 
began to speculate whether NAC and GSH were specifically reversing the IFN-γ intracellular 
killing, the ceftazidime extracellular killing, or both.  Or in other words, was ROS important for 
the IFN-γ effect, the ceftazidime effect, or both?   
 We first evaluated the role of ROS in IFN-γ activated macrophages.  We showed that 
antioxidants NAC and GSH could both partially reverse the intracellular killing of Burkholderia 
due to IFN-γ-activated macrophages (Figure 5.4).  Furthermore, using the bone marrow 
macrophages from phox-/- mice, which lack a functional NADPH phagocyte oxidase, we showed 









































Figure 5.4:  IFN-γ mediated intracellular killing is partially dependent on ROS.  RAW 
264.7 macrophages were pre-activated with IFN-γ (10 ng/ml) for 18 hrs and treated with NAC 
(50 mM) or GSH (50 mM) for the last 3 hrs of the pr-t eatment period.  Treatments were then 
washed away and macrophages were infected with B. t ailandensis.  Intracellular bacterial 
burden was assessed 6 hours after MEM was reapplied to macrophages by plating serial dilutions 
of lysates (see Materials and Methods for more details).  a > b > c > d (P < 0.05).  Data is 
representative of two independent experiments run in quadruplicate.   
 
C57BL/6 background-matched controls (Figure 5.5).  Taken together, these results suggest a 
partial role for ROS in the mechanism of IFN-γ mediated killing of intracellular bacteria. 
 
 GSH reverses ceftazidime killing of bacteria.  After showing only a partial role for 
GSH to reverse IFN-γ mediated intracellular killing, we were especially interested in whether or 






































Figure 5.5:  IFN-γ induced ROS kills intracellular Burkholderia.  Resting bone marrow 
macrophages from C57BL/6 or phox KO mice were infected with B. thailandensis for 1 hr and 
subsequently treated with ceftazidime (3 µg/ml) or IFN-γ (10 ng/ml) for 18 hrs.  Cell lysates 
were then plated to determine remaining intracellular bacteria burden.  Synergy between IFN-γ 
and ceftazidime was determined separately for C57BL/6 macrophages and phox -/- macrophages.  
Statistically synergistic interactions were assessed by two-way ANOVA (*P = 0.0164). 
 
In our macrophage-free bacteria killing assay, we showed that GSH reversed ceftazidime 
mediated killing in a dose-dependent manner, with complete reversal of killing at 100 mM 
(Figure 5.6).  Although we do not suspect that thisresult implies that the mechanism of 
ceftazidime killing is ROS-mediated, further investiga ion into the mechanism of this reversal is 
required to fully understand this effect.  Taken together, these results with GSH reversal of both 
IFN-γ and ceftazidime mediated killing in separate compartments, suggests a dual role for this 
antioxidant to interfere with immuno-antimicrobial synergy either through scavenging IFN-γ 
































Figure 5.6:  GSH reverses ceftazidime killing of Burkholderia.  B. thailandensis was 
incubated for 18 hours with ceftazidime (10 µg/ml) with or without GSH in a macrophage-free 
bacteria killing assay.  Surviving bacteria were enumerated by plating dilutions of remaining 
bacteria in wells.  Significant differences were assessed by one-way ANOVA, a > b > c > d (P < 
0.05).  Graph is representative of two independent experiments with treatment groups run in 
triplicate or quadruplicate. 
DISCUSSION 
 We have shown previously that IFN-γ synergizes with ceftazidime to control intracellular 
bacterial burden from Burkholderia infected macrophages as well as protect mice from lethal 
infection with Burkholderia (28).  In chapter 4 we showed that IFN-γ induced ROS was essential 
for the synergy observed between IFN-γ and ceftazidime, and furthermore, that this ROS 
response prevented vacuolar escape of Burkholderia.  In the present chapter we expanded on the 
individual contributions of both ceftazidime and IFN-γ to the synergistic interaction.  We show 
that while IFN-γ and ceftazidime synergistically interact to reduce bacterial burden 
intracellularly, we also show that they synergistically interact to reduce extracellular bacterial 
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burden.  We found that each drug contributes primarily to control of bacterial numbers in either 
the extracellular or intracellular compartment, butalso that numbers of bacteria in one 
compartment can impact the other compartment. 
 We first discovered that other bactericidal, but not bacteriostatic, antibiotics were capable 
of interacting with IFN-γ to synergistically reduce bacterial burden inside inf cted macrophages.  
This result showed that immuno-antimicrobial synergy is a broadly observed interaction with 
other classes of bactericidal antibiotics.  We then showed that ceftazidime primarily controls the 
extracellular bacterial burden in our macrophage inf ction model.  Through experiments that 
measured extracellular bacterial burden either withor without the presence of infected 
macrophages (Figure 5.2), we showed that ceftazidime was responsible for the reduced 
extracellular bacteria numbers.  We showed that IFN-γ activated macrophages, but not IFN-γ 
itself, only contributed to enhanced reduction of extracellular bacterial burden when ceftazidime 
was present.  Although we have speculated that IFN-γ induced ROS may cross the membrane 
and interact with ceftazidime in the extracellular environment, we have already taken steps 
towards confirming a lack of interaction between ceftazidime and ROS in the extracellular 
compartment.  We combined supernatants from IFN-γ activated macrophages with ceftazidime, 
in a modified and shortened bacteria killing assay, and found no evidence of interaction resulting 
in increased control of bacterial burden (Figure A9).  Although supernatants from IFN-γ 
activated and infected macrophages may combine with ceftazidime to increase control of 
bacterial burden, we suspect that this is not the cas , since there was no effect and not even a 
trend for an effect in Figure A9 using uninfected clls.  Therefore, we suggest that the IFN-γ 
activated macrophage ability to contribute to ceftazidime control of extracellular bacterial burden 
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is specifically due to IFN-γ prevention of replication, cell-to-cell spread, or decreased 
macrophage lysis. 
 We then showed that IFN-γ activated macrophages killed intracellular Bu kholderia and 
also prevented intracellular replication, while ceftazidime pre-treated macrophages were unable 
to significantly control intracellular bacterial burden.  IFN-γ also appeared to inhibit cell-to-cell 
spread of infection in microscopy images of Burkholderia infected macrophages.  In these three 
ways, it is clear that IFN-γ, and IFN-γ alone, controlled intracellular bacterial burden.  We also 
observed a partial reversal of the IFN-γ mediated killing effect of IFN-γ activated macrophages 
owing to NAC or GSH, suggesting a partial role for ROS in the IFN-γ mediated killing of 
intracellular Burkholderia. 
 Our results enable us to present a novel model to describe the dynamics of the 
macrophage infection assay (Figure 5.7).  In the absence of antibiotic, extracellular bacteria 
replicate and are a source for further infection of macrophages.  In the absence of IFN-γ, and 
more specifically IFN-γ induced ROS, intracellular replication and cell-to-cell spread both go 
unchecked and eventually high bacteria numbers may rupture the macrophages, spilling back 
into the extracellular compartment.  Therefore we predict there is some level of constant 
exchange of bacteria between the intracellular and extracellular compartments which makes the 
control of one compartment’s killing inadequate to reduce overall numbers in the system as a 
whole.  It is only when both extracellular and intracellular bacteria numbers are controlled 
simultaneously that the synergistic interaction is achieved.  This explanation also clarifies why 
bacteriostatic antibiotics were not synergistic with IFN-γ. 
    
 
 
Figure 5.7:  Compartmentalized 
and ceftazidime.  During the macrophage infection assay 
bacteria in the intracellular and extracellular compartments through invasion 
eventual rupture out.  Therefore it is only 
replication, combined with ceftazidime control of extracellular
achieved with low bacterial burden in the system as a whole.
ceftazidime and ceftazidime + IFN
infection assay.  Although filamentous 
bacteria in the combination therapy treated macrophages, their role is undetermined as of now.  
Further experimentation will be required to determine their role in our macrophage infection 
assay (see Chapter 6 for suggested future experiments).
 
 We believe our data suggest that there is no interaction between IFN
ceftazidime in the same compartment
explain the observed synergism.  Ceftazidime would have to be taken up into the cell for a drug 
interaction to occur in the intracellular compartment.  We had previously determined 
intracellular concentrations of ceftazidime to be around 50 fold lower than the MIC.  To confirm 
that low levels of ceftazidime didn’t have a role in enhancing IFN
that any ceftazidime that was taken up during the 18 hour pre
sufficient to control intracellular bacteria on its own or enhance the IFN
It is unlikely that IFN-γ induction of ROS responses could be enhancing the ceftazidime killing 
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of extracellular bacteria during the macrophage infction since H2O2 is typically degraded before 
it can significantly accumulate across a membrane (37).  But to confirm this theory, we showed 
that IFN-γ had no direct role in extracellular killing (Figure 5.2B) and supernatants from IFN-γ 
activated macrophages were unable to interact with ceftazidime to reduce bacteria (Figure A9). 
 In chapter 4 we had shown a strong role for IFN-γ induced ROS in the synergistic control 
of intracellular bacterial burden between IFN-γ and ceftazidime.  It may seem a contradiction 
then, that in this chapter we show that IFN-γ pre-activated macrophages kill intracellular bacteria 
and yet we only show a minor role for ROS in the mechanism of this killing.  We believe 
differences in timing between infection and IFN-γ activation may account for the observed 
difference in the contribution of ROS.  For example, when resting macrophages are stimulated 
with both Burkholderia and treatments around the same time we see that IFN-γ induced ROS are 
critical for synergy owing to complete reversal of intracellular control of bacterial burden with 
addition of antioxidants.  In contrast, when we pre-activate macrophages first, with 18 hours of 
IFN-γ stimulation, and subsequently infect with Burkholderia, we see only a small reversal of the 
IFN-γ killing with antioxidants, suggesting only a small ro e for ROS as the mechanism of 
killing. 
 One explanation for the observed deficiency of ROS mediated killing in the pre-
activation model may be that IFN-γ activation in the absence of bacterial stimulation elicits a 
different degree of ROS response than simultaneous c -activation.  This explanation is supported 
by other studies which have similarly shown differenc s in the types or degrees of macrophage 
responses between macrophages pre-activated with cytokines alone versus macrophages 
simultaneously activated with cytokines and pathogens (38-40).  Furthermore, in our pre-
activation studies, we imagine that any NAC and GSH taken up during the 3 hour incubation is 
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likely used immediately to scavenge ROS or serve oth r antioxidant roles.  We predict that a 
more robust ROS response is elicited after bacterial infection of the pre-activa ed macrophages 
and that the ROS does significantly contribute to the observed time-depend nt killing of 
intracellular Burkholderia, however there are no longer sufficient antioxidants available to 
reverse the killing and show the strong role for ROS.  Another likely explanation for the 
discrepancy between the role of ROS between the two models of infection, is that in the first 
model, GSH addition to the combination therapy probably reversed some of the ceftazidime 
mediated extracellular killing.  This would allow the extracellular pool of bacteria to replicate 
unchecked and infect more healthy cells, which could help explain the apparently high role of 
ROS. 
 In this chapter we showed that GSH completely reversed ceftazidime-mediated killing in 
a macrophage-free bacteria killing assay.  One explanation for this effect is that GSH interfered 
with the common mechanism of antibiotic killing invol ing ROS generation in bacteria (41-45).  
However, several recent studies show strong evidence against a ROS-dependent mechanism of 
antibiotic killing (46-48).  Additionally, one study specifically showed that exogenous 
glutathione could protect E. coli against bactericidal antibiotics as well as bacteriostatic 
antibiotics which do not induce oxidative stress, suggesting that the protection afforded by GSH 
extends past a purely ROS-scavenging role (49).  Studies show that other antioxidants such as 
ascorbic acid are also capable of protecting against ntibiotic killing, suggesting a broader 
protective effect (50, 51).  Taken together these rults suggest that it is unlikely that GSH, in our
study, interfered with a ROS-mediated killing mechanism of ceftazidime. 
 One possible explanation for the GSH effect of inhibiting antibiotic killing is that GSH 
has in some way blocked antibiotic activity, either through direct reaction and inactivation or 
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through conjugation.  Perhaps the best way to show whether GSH blocks antibiotic activity 
would be to pre-treat bacteria with high doses of GSH first, wash cells, and then add antibiotics.  
In this way, bacteria would be pre-loaded with the antioxidant, and ceftazidime would be unable 
to directly interact with it.  One study has already conducted a similar study in E. coli and has 
shown that pre-treatment of E. coli with GSH or ascorbic acid did not protect bacteria ag inst 
subsequent treatment with streptomycin, suggesting that GSH must be present with the antibiotic 
to exert its protective effect (50).  This result strongly suggests that in our experiments, GSH and 
directly blocked ceftazidime activity or inactivated the antibiotic. 
 In mammalian cells, protection from electrophiles and xenobiotic compounds has been 
shown to occur through conjugation of these compounds to GSH, a reaction that is catalyzed by 
glutathione-S transferases (GST) followed by secretion from the cell (52).  Bacteria also possess 
GSTs and it is speculated that bacteria may be able to similarly use GSH conjugation to reduce 
or eliminate the threat of antibiotics, although no studies have shown this to be true at this time 
(50, 53).  It is possible that in our experiments Burkholderia uses GSTs to conjugate GSH to 
antibiotics and eliminate their threat.  However, if we were to find that antioxidants besides GSH 
also protect Burkholderia against antibiotics, then GSTs would not be implicated in the 
protection, since conjugation specifically relies on a source of GSH and not just any antioxidant.  
Although we have not conducted experiments with other antioxidants, studies by Goswami et. al. 
have shown a role of other antioxidants such as ascorbic acid to protect bacteria from deadly 
antibiotics (50, 54).  Therefore we believe it is improbable that GSTs are involved with 
antioxidant protection of Burkholderia from ceftazidime, and instead, direct reaction and 
inactivation of antibiotics by antioxidants may be more likely.  
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 Our results also suggest against the use of the standard kanamycin protection assay to 
define specific and individual IFN-γ effects.  The kanamycin protection assay, usually used as a 
tool to study the cellular response to IFN-γ, is a type of macrophage infection in which 
macrophages are treated with extracellular antibiotics during the entire experiment.  The purpose 
of the addition of extracellular antibiotics is to enable the exclusive study of intracellular effects.  
Instead, we propose that in most macrophage infection models any addition of extracellular 
antibiotics is likely enhancing the overall bacterial killing in the system, which may artificially 
enhance the observed effect of the IFN-γ alone.  Antibiotic killing in the extracellular 
compartment limits the number of viable bacteria that can infect healthy cells.  In this way, the 
intracellular bacterial burden is likely to be much lower than in these cells than in cells only 
treated with IFN-γ.  Furthermore, in studies that monitor cell viability, even a minor decrease in 
macrophage viability could be due to rupture of macrophages and release of hundreds or 
thousands of bacteria back into the extracellular sp ce.  If it weren’t for the antibiotics in the 
extracellular compartment, these bacteria would likely re-infect nearby healthy cells.  Both of 
these scenarios warn that scientists may be inadvertently documenting results as an effect of 
IFN-γ alone, when in fact, it is more probably an example of immuno-antimicrobial synergy, 
similar to our IFN-γ plus ceftazidime treated macrophages.  Therefore, we caution against the 
kanamycin protection assay as a model to describe a single intracellular treatment effect.  
 In conclusion, we have shown that the major mechanism of immuno-antimicrobial 
synergy is due to separate and compartmentalized killing of IFN-γ and ceftazidime.  We 
provided evidence that IFN-γ alone kills intracellular bacteria and we also showed a role for 
ROS responses as a mechanism of this killing.  Ceftazidime alone was shown to kill extracellular 
bacteria and killing was completely reversed by GSH.  Future studies are required to determine 
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the exact mechanism by which GSH protects against antibiotics, but regardless, we show 
important and relevant evidence that the antioxidant GSH effectively eliminates the killing 
capacity of ceftazidime.  This result may have implications for avoidance of antioxidant 
supplements during infection, as they may inactivate antibiotics.  Taken together, our results 
suggest that the classical macrophage infection model is a dynamic system of intracellular and 
extracellular bacteria.  We further conclude that control of bacterial burden in each compartment 
can lead to strong synergistic reduction of bacteria from the entire system.  Knowing the role of 
compartmentalized killing in immuno-antimicrobial therapy opens avenues to explore other 
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CHAPTER 6:  OVERALL SIGNIFICANCE AND  
FUTURE DIRECTIONS OF SPECIFIC AIMS 
 
RESEARCH SUMMARY AND SIGNIFICANCE 
 The main goal of the research presented in this dissertation was to determine the 
mechanism by which IFN-γ interacts with ceftazidime to synergistically eliminate intracellular 
bacterial burden inside infected macrophages.  In chapter 3 we explored several potential 
mediators of immuno-antimicrobial synergy.  While most of our results in chapter 3 showed 
evidence against our targets as major mediators of the synergistic effect, we maintain that these 
negative data may help future scientists, especially those which pursue a similar topic.  In 
chapter 4 we identified an interaction between IFN-γ induced ROS responses and ceftazidime to 
synergistically reduce intracellular Burkholderia.  Furthermore we demonstrated a role for IFN-γ 
induced ROS to prevent vacuolar escape which led to a lack of actin polymerization and reduced 
intracellular replication.  In chapter 5 our result provided evidential support for a new model to 
describe the dynamics of the classical macrophage infect on model.  We also determined the 
separate independent roles for IFN-γ and ceftazidime.  IFN-γ controlled intracellular replication 
and spread of infection, due in part to ROS responses, while ceftazidime alone killed 
extracellular bacteria. 
 We believe that our new understanding of the role of compartmentalized killing in 
immuno-antimicrobial therapy creates new possibilites for drug combinations for enhanced 
treatment of not only B. pseudomallei infection, but potentially other Gram negative intracellular 
pathogens, too.  Just as we have already shown that other bactericidal antibiotics are capable of 
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synergizing with IFN-γ, we also propose that other compounds or drugs which enhance 
macrophage killing capacity or interfere with the intracellular lifestyle intracellular pathogens, 
may synergize with ceftazidime therapy.  The best candidates for such compounds would be 
agents that directly induce a strong, endogenous IFN-γ response or induce endogenous ROS 
production, a mediator of IFN-γ responses.  We have already shown evidence of the efficacy of 
both of these approaches.  We previously found that cationic liposome-DNA complex (CLDC) 
elicited a particularly strong IFN-γ response which could then interact with ceftazidime treatment 
to synergistically enhance survival rates of mice to le hal B. pseudomallei challenge (1, 2).  We 
also have also already shown that other ROS-inducers, such as BSO, are capable of synergy with 
ceftazidime, which supports the use of other ROS stimulators as non-specific, antibiotic 
enhancing agents.   
 The effectiveness of the immuno-antimicrobial therapy suggests the possibility for 
decreasing the dose of ceftazidime given to patients clinically if IFN-γ, IFN-γ inducing drugs, or 
other ROS-inducing drugs are given alongside antibiotic treatment.  Additionally, immuno-
antimicrobial therapy could reduce the length of the suggested two-week intravenous ceftazidime 
treatment since the intravenous antibiotic phase of melioidosis treatment is the most expensive 
and invasive portion of treatment and is not practic l where access to healthcare is limited (3-5).    
Our results with in vivo administration of BSO with sub-therapeutic doses of ceftazidime 
showed 100% survival of mice, suggesting that decreased doses of ceftazidime may still fully 
protect against melioidosis when administered with ROS-inducing drugs.  Furthermore, the dose 
of BSO that was used in our study, 2 mmol/kg once daily for three days, was well below the 
suggested dose of 8 mmol/kg every 4 hours (6), suggesting that we have already found a lower 
dose of BSO to be successful as well. 
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 In conclusion, we have discovered a novel platform for future studies on drug 
combinations to enhance pathogen elimination.  We suggest that a drug which only targets 
intracellular killing may combine well with a drug that only targets extracellular killing to 
synergistically reduce the number of bacteria in the system as a whole, reduce spread of the 
infection, and maintain the health of host cells.  Additionally, our results warn against the use of 
certain ROS-scavengers and antioxidants as nutritional supplements, because they may mitigate 
the potency of antibiotic treatment during acute inf ction through eliminating the beneficial host 
ROS response or through inactivation of antibiotics. 
 
UNANSWERED QUESTIONS AND FUTURE DIRECTIONS OF SPECIFIC AIMS: 
 We have answered the major questions that we intended through our research into the 
mechanism of immuno-antimicrobial synergy, however our results have generated many more 
questions that now need to be answered in order to fully understand the synergy.  We have 
outlined these questions below and suggest experiments towards finding their answers. 
 
How does ROS prevent vacuolar escape? 
 We found that IFN-γ and BSO, another ROS inducing drug, prevented Burkholderia from 
escaping the phagolysosome.  The significance of this result cannot be overstated.  By preventing 
vacuolar escape, ROS can inhibit replication in the cytoplasm, actin-tail polymerization, and also 
cell-to-cell spread of the infection.  Furthermore, this IFN-γ induced ROS effect has been 
confirmed for other intracellular pathogens (7-9).  But how ROS prevents vacuolar escape is still 
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an unanswered question.  One possibility is that increased ROS, due to IFN-γ activation, kills 
bacteria in the phagosome before they have a chance to escape.  Increased ROS could kill 
bacteria directly through irreparable damage to DNA and protein, or ROS could interact with 
other phagolysosome components to increase killing.  For example, some scientists speculate 
that ROS may gain better access to bacteria due to pores or holes formed by antimicrobial 
peptides (10).   
 Another alternative is that ROS responses in the phagosome down regulates gene 
expression or otherwise interferes with the T3SS-3 apparatus, which is necessary for rapid 
escape of the vacuole (11-13).  Future studies should l ok at gene expression levels of 
Burkholderia trapped in the phagolysosome of IFN-γ treated macrophages, to determine if 
components of their T3SS-3 apparatus and/or protein effectors are down-regulated compared to 
bacteria in untreated macrophages.  However, we foresee that differences in gene expression 
may simply arise from imprecise timing of the collection of control bacteria.  Therefore a more 
straight-forward solution would be to infect macrophages with mutant bacteria lacking a 
functional T3SS-3 and then either treat with IFN-γ or leave macrophages untreated.  Mutant 
bacteria will be unable to escape the phagolysosome regardless of treatment, however, if the 
increase in ROS, due to IFN-γ, is directly microbicidal, we would expect greater int acellular 
killing in the IFN-γ treated macrophages.  This result would suggest that IFN-γ, through 
induction of ROS, creates a phagolysosome which is more toxic to bacteria. 
 
Does increased time in phagolysosome equate to increased killing? 
 If increased ROS due to IFN-γ or BSO isn’t found to directly kill Burkholderia in the 
phagolysosome, and instead, ROS is suspected to interfere with T3SS-3 function, then we could 
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ask the question does prevention of vacuolar escape actually lead to increased killing?  We 
would hope that increased exposure of Burkholderia to phagosome contents such as AMPs, 
lysozyme, and proteases would lead to increased killing (10), however studies show that B. 
pseudomallei is resistant to many host-derived antimicrobial defenses (14, 15).  Therefore, it is 
important to determine whether Burkholderia that fail to escape the phagosome due to IFN-γ 
induced ROS, are eventually killed or instead regain the ability to escape, exhibit delayed escape, 
or perhaps remain inside the phagolysosome for an extended period of time.  We could easily 
test these ideas using confocal microscopy to take short-interval time-lapse images of a particular 
IFN-γ treated macrophage with intracellular Burkholderia.  This experiment would more 
definitively show whether preventing vacuolar escape has the degree of impact that we suspect.   
 
Would immuno-antimicrobial therapy be an effective treatment for chronic melioidosis? 
 All of our studies on immuno-antimicrobial therapy have focused on treatment of acute 
melioidosis both in vitro and in vivo.  However, we are curious if IFN-γ and ceftazidime might 
be effective treatment for chronic melioidosis, in which an infection has already been established 
for quite some time.  C57BL/6 mice are good models for chronic melioidosis as they can carry 
heavy bacteria loads in liver and spleen for several weeks before succumbing to death (16).  
Future studies will investigate the effectiveness of IFN-γ or BSO combination with ceftazidime 
in a chronic melioidosis mouse model in the hope that immuno-antimicrobial therapy will be 
equally effective at later points of infection.  However, some studies suggest that IFN-γ is not 
helpful, and instead is detrimental, in some models of established infections (17).  There is a 
correlation between increased serum IFN-γ and increased severity of disease and prognosis in 
BALB/c mice as well as human patients with melioidosis (17, 18).  Furthermore, a possible 
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explanation for the high susceptibility of BALB/c to B. pseudomallei has been its high, but 
slightly delayed, IFN-γ response (17, 19).  However these studies were condu ted with acute 
melioidosis.  We still believe that in a chronic model IFN-γ would be beneficial and enhance the 
efficacy of ceftazidime treatment. 
 
Are mitochondrial ROS and NADPH phagocyte oxidase-generated ROS equally important 
for the IFN-γ effect? 
 It is well known that IFN-γ increases expression of ROS in macrophages as well NADPH 
phagocyte oxidase subunit expression (20, 21).  In our system, we have not evaluated whether 
IFN-γ substantially increases mitochondrial ROS production, although activation of NADPH 
oxidase has been shown to increase mitochondrial ROS production (22), and it is conceivable 
that mitochondrial ROS contributes to some threshold of total cellular ROS required for the IFN-
γ effect.  GSH is known to have similar distribution within the cytoplasm, mitochondria, and 
nucleus, though we are unaware of any studies that have identified the GSH concentration or 
localization in vacuoles such as the phagosome (23).  Precursors to GSH, such as NAC, have 
been shown to eliminate mitochondrial ROS as well as reduce the respiratory burst from 
polymorphonuclear cells (24, 25).  Therefore we should determine whether addition of GSH to 
our system has specifically scavenged NADPH oxidase-generated ROS, which we assume to be 
the main source of increased ROS due to IFN-γ stimulation, or mitochondrial ROS.   
 We propose future experiments to first test whether mitochondrial ROS actually plays a 
role in the IFN-γ effects.  First we would detect an increase in total intracellular ROS due to IFN-
γ using carboxy-H2DCFDA and flow cytometry.  We would compare this increase in total ROS 
to any increase in mitochondrial ROS using mitoSOX red, a dye that detects superoxide 
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specifically from mitochondria.  This experiment would indicate whether mitochondrial ROS is a 
component of IFN-γ induced ROS, though if it were not, we could not exclude the possibility 
that mitochondrial ROS still contributes to the overall threshold of intracellular ROS which may 
be important for IFN-γ killing and prevention of vacuolar escape.  We could therefore use a 
specific mitochondrial antioxidant, such as mitoTEMPO (26) or SS peptides (27), to determine 
the necessity of mitochondrial ROS to IFN-γ mediated killing and prevention of vacuolar escape.  
We could similarly use an NADPH oxidase inhibitor, such as apocynin (22) to determine the 
relative importance of NADPH oxidase to IFN-γ mediated killing or vacuolar escape, though a 
more definitive result would come from measuring the killing efficiency of bone marrow 
macrophages from phox -/- mice pre-activated with IFN-γ and compared to a wild-type control.   
 
Can other roles of GSH and NAC explain the reversal of immuno-antimicrobial synergy? 
   In chapter 4 we showed that NAC and GSH similarly reversed IFN-γ and ceftazidime 
immuno-antimicrobial synergy and provided evidence that this effect was due to their 
antioxidant properties.  In our macrophage infection model, GSH and NAC have only shown a 
measurable effect, namely the reversal of synergy, when ROS is known to be increased.  
Although this result is consistent with a ROS-scavenging role, we cannot exclude the possibility 
that GSH and NAC may function in a different, non-antioxidant role to reverse the immuno-
antimicrobial synergy, especially because we have nev r thought to test the ability of GSH and 
NAC to reverse ROS-independent killing before now.   
 NAC has also been shown to delay cell death and inhibit apoptosis through down-
regulation of caspase-8 protein and mRNA expression, as well as inhibition of caspase-3 and 
caspase-7 proteolytic processing (28-30).  Therefore it is a possibility that NAC, rather than 
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scavenging IFN-γ induced ROS, interfered with programmed cell death, which is thought to be a 
mechanism of macrophages to eliminate the intracellular niche for intracellular pathogen 
replication (31, 32).  To test this, we propose future experiments with fluorescent microscopy of 
macrophage infections and simultaneous treatment with IFN-γ and NAC.  If NAC serves an 
antioxidant and ROS-scavenging role, we should see bacterial actin tail formation and replication 
in cytoplasm inside macrophages treated with IFN-γ + NAC combined treatment, signifying 
escape from phagolysosomes.  On the other hand, if NAC functions through inhibition of 
programmed cell death, we will likely see preventio of vacuolar escape similar to IFN-γ.  
Similar studies could be conducted with GSH. 
 Finally, GSH has been shown to inhibit B. cenocepacia adherence to and uptake into 
respiratory epithelial cells due to alteration of redox status of surface proteins (33).  Therefore, 
GSH could have inhibited uptake of B. thailandensis in our macrophage infections.  However we 
do not believe this is the case since inhibiting uptake would hypothetically lead to lower 
intracellular numbers instead of higher ones as we have regularly seen with GSH treatment in 
our experiments. 
 
Does infection of pre-activated macrophages eventually induce a robust ROS response? 
 We have speculated in chapter 5 that pre-activation of macrophages with overnight 
incubation with IFN-γ likely elicits a different degree of ROS response compared to 
macrophages simultaneously stimulated with IFN-γ and Burkholderia.  However we suspect that 
pre-activation with IFN-γ followed by infection with Burkholderia, would likely elicit a similar 
response to co-stimulation, if given the same amount f time.  This is an important point, since 
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we argue that ROS responses probably play a larger role in IFN-γ mediated killing, than our 
assay allows for us to determine.  In order to determine if infection of pre-activated macrophages 
eventually induces a robust ROS response, we would measure intracellular ROS production in 
these macrophages over time starting just before infection and sampling at various time points 
until 18 hours post infection.  We would then compare the maximal ROS response to the ROS 
responses of macrophages co-stimulated with IFN-γ and bacteria for 18 hours.  These 
experiments would determine the relative degrees of ROS responses with pre-activation versus 
co-stimulation. 
 
Do bactericidal antibiotics kill B. pseudomallei through a ROS-dependent mechanism? 
 In the discussion section of chapter 5 we raised th  question of how GSH protects 
bacteria from antibiotic killing.  One explanation is that GSH may function as an antioxidant to 
scavenge deadly ROS generated in bacteria by the common mechanism of antibiotic-mediated 
death (34-38).  However many recent studies provide evidence that antibiotics do not kill 
through ROS-mediated pathways (39-41).  To more definitively determine if B. pseudomallei is 
killed by antibiotics in a ROS-dependent manner, we could treat a katG mutant strain, lacking 
catalase and peroxidase activity, with antibiotics and compare its susceptibility to a wild-type 
strain.  Antioxidant and ROS-scavenging mutant bacteria have similarly been used to determine 
the role of ROS in antibiotic killing (40, 42, 43).  If antibiotics kill through ROS-dependent 
mechanisms, a mutant incapable of degrading the toxic ROS generated by antibiotics, would be 
more susceptible to antibiotic killing, lowering the MIC for a particular antibiotic compared to a 
wild-type strain control.  We do not suspect a ROS-mediated mechanism for ceftazidime 
lethality, therefore we would not expect a katG mutant to be more susceptible to ceftazidime. 
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How do GSH and other antioxidants protect bacteria from ceftazidime? 
 If GSH and other antioxidants don’t protect against antibiotics by scavenging antibiotic 
induced ROS, then what is the mechanism of antioxidant protection?  In chapter 5 we discussed 
evidence that suggests that antioxidants play a role in either blocking or inactivating antibiotics 
(44-46).  Evidence for antioxidant inactivation or blocking of antibiotics comes from studies that 
show that exogenous but not endogenous GSH is protective (44) and GSH must be present at the 
time of antibiotic treatment to exert its protective effects (45).  Additionally, GSH may not be 
protective for Gram positive bacteria suggesting a Gr m negative specific component to the 
protective effect (47).  We suggest an initial experim nt to determine whether, in our system, 
ceftazidime is inactivated through direct reaction with GSH or conjugation to GSH.  If other 
antioxidants besides GSH protect Burkholderia against different classes of antibiotics, then GSTs 
are not likely involved in the GSH protection against antibiotics since GSTs only use GSH for 
conjugation and not just any antioxidant.  Further studies would need to be conducted to 
understand any direct reaction or inactivation of ceftazidime with antioxidants. 
  
What role do filamentous bacteria play in our macrophage infection model? 
 We have seen through microscopy that filamented Burkholderia often make up a large 
proportion of the remaining intracellular and extracellular bacteria in the macrophages treated 
with the combination therapy (Figure 5.1).  We are curious about the role of filamentous bacteria 
in our macrophage infection system, especially since studies show them to have decreased 
virulence compared to nonfilamentous Burkholderia (48).  Chen found that filamentous bacteria 
reverted back to a nonfilamentous form after antibio cs were removed, but these bacteria were 
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resistant to antibiotics.  Similarly, our preliminary experiments suggest that filamentous bacteria 
may be resistant to high doses of antibiotics (Figure A10).  If filamentous bacteria show more 
antibiotic resistance, are these bacteria responsible for infection relapse?  Why are there more 
filamentous bacteria in macrophages treated with the combination therapy?  Future 
investigations should investigate these still unanswered questions. 
 
Future directions summary 
 As illustrated in this chapter, there are several new directions in which we could take this 
project.  We believe that one of the most pressing questions is whether both NADPH phagocyte 
oxidase generated ROS and mitochondrial generated ROS are both important for the IFN-γ 
effects seen in immuno-antimicrobial synergy.  Another important question to address is how 
ROS can prevent vacuolar escape of bacteria in the phagolysosome.  Future studies will certainly 
address these questions and the others suggested in this chapter.  It is our hope that we can better 
understand the mechanism of immuno-antimicrobial synergy and use our understanding to 
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APPENDIX I:  SUPPLEMENTAL FIGURES 
Timecourse of CXCL10 Protein Concentration
in Supernatants of Infected RAW cells


























Figure A1:  Timecourse of CXCL10 protein concentration in supernatants during 
macrophage infection.  RAW 264.7 macrophages were infected with B. thailandensis and 
treated with either ceftazidime (10 µg/ml), IFN-γ (10 ng/ml), or the combination of ceftazidime 
and IFN-γ.  At 6, 8, 10, 13, and 18 hours after treatment a sample of supernatant was taken from 
wells and assessed for CXCL10 protein concentration by ELISA.  Statistical differences 
compared to the untreated control were assessed for each time point by repeated measures two-






Bacteria Killing Assay with Ceftazidime











































Figure A2:  Additive inhibition effects of LL-37 and ceftazidime when simultaneously 
added to E. coli.  E. coli was grown to mid-log phase and subsequently treated simultaneously 
with ceftazidime (50 ng/ml), LL-37 (15 µg/ml), or ceftazidime and LL-37 for 6 hours on a rotary 
shaker (200 rpm).  Surviving bacteria were enumerated by plating serial dilutions of remaining 
bacteria on LB agar followed by colony counts 24-48 hours later.  Statistical differences were 
assessed by one-way ANOVA and Tukey’s post-test, a > b > c > d, P < 0.05.  Data is 




Bacteria Killing Assay with Burkholderia








































Figure A3:  LL-37 treated bacteria are more resistant to growth inhibition by ceftazidime.  
E. coli was treated with LL-37 (15 µg/ml) for one hour and subsequently treated with 
ceftazidime (50 ng/ml) for an additional 6 hours in 96-well plates.  Surviving bacteria were 
enumerated by plating serial dilutions of remaining bacteria on LB agar followed by colony 
counts 24-48 hours later.  Statistical differences w re assessed by one-way ANOVA and Tukey’s 






Bacteria Killing Assay with Ceftazidime










































Figure A4:  Synergistic growth inhibition of Burkholderia with ceftazidime and LL-37 
combination.  B. thailandensis was grown to mid-log phase, diluted in 1 mM potassium 
phosphate buffer, and added to 96-well plates at a density of 1x106 CFU/ml.  Bacteria was 
initially incubated with LL-37 (30 µg/ml) for 1 hour.  After 1 hour, a TSB solution was added to 
the wells so that the final concentration was 1x.  Ceftazidime was added to the wells and plates 
were incubated an additional 5 hours to make the total treatment time 6 hours.  Surviving 
bacteria were enumerated by plating serial dilutions f wells on LB and counting colonies 24-48 
hours later.  Statistically significant differences were assessed by one-way ANOVA and Tukey’s 
post-test, a > b > c > d, P < 0.05.  Data is representative of one experiment with treatment groups 
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Figure A5:  Ceftazidime and H2O2 only inhibit growth during bacteria killing assay.  B. 
thailandensis was grown to mid-log phase and then plated into a 96-well plate with ceftazidime 
(750 ng/ml) and H2O2 (20 µM) with a total well volume of 200 µl.  Plates were incubated for 6 
hours and at various time points bacteria were plated from wells to determine increasing bacterial 
burden.  Statistical differences between treated and untreated group were assessed at each time 
point by two-way ANOVA, P < 0.05.  Data is representative of one experiment with treatment 












































Figure A6:  Ceftazidime and H2O2 do not interact to synergistically kill Burkholderia.  B. 
thailandensis was grown to mid-log phase, and then plated into 96-well plates (starting density 
shown as dashed line) with either ceftazidime (10 µg/ml), H2O2 (80 µM), or the combination of 
both treatments for 3 hours at 37°C.  Surviving bacteria were enumerated by plating serial 
dilutions of remaining bacteria in wells after 3 hours.  Data is representative of one experiment 








































Figure A7:  Ferrous sulfate prevents growth inhibition due to ceftazidime or H2O2.  B. 
thailandensis was grown to mid-log phase and then plated into a 96-well plate at an initial 
density of 1x106 CFU/ml.  Ceftazidime (750 ng/ml), H2O2 (20 µM), and/or ferrous sulfate were 
added to bacteria resulting in a total well volume of 200 µl.  Plates were incubated for 6 hours at 
37°C.  Remaining bacterial burden was assessed by plating serial dilutions of wells onto LB agar 
after 6 hour treatment.  Statistical differences betwe n treated groups and untreated control were 
assessed for each concentration of ferrous sulfate addition by two-way ANOVA, *P < 0.05.  




Figure A8:  Higher proportion of LAMP
treated macrophages.  RAW 264.7 macr
treated for 10-12 hours with IFN
fluorescent microscopy (see Materials and Methods).  Above images show untreated (left) and 
IFN-γ treated (right) single color images (top) and overlays (bottom) of macrophages stained for 
CD11b (purple), nuclei (blue), Burkholderia
of 10 fields of view for 2 independent experiments.
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-1 colocalization with Burkholderia
ophages were infected with B. thailandensis
-γ (10 ng/ml).  After treatment, cells were prepared for 
 (red), and LAMP-1 (green).  Data are representative 
 
 











































Figure A9:  Supernatants from IFN-γ activated macrophages do not interact with 
ceftazidime to synergistically kill B. thailandensis.  RAW 264.7 macrophages were stimulated 
with IFN-γ (10 ng/ml) for 18 hours.  Then supernatants were combined with ceftazidime (10 
µg/ml) and incubated with B. thailandensis in 96 well plates for 6 hours before plating serial 
dilutions of well contents to enumerate surviving bacteria.  Statistical differences were assessed 
by one-way ANOVA, a > b, P < 0.05.  Data is representative one experiment with treatment 


















Figure A10:  Filamentous bacteria are resistant to high doses of ceftazidime.  Escherichia 
coli were incubated overnight with sub-lethal concentrations of ceftazidime to induce 
filamentation.  Filamentous and non-filamentous bacteria were then inoculated into 96-well 
plates at the same initial density (as determined by plating) and incubated with 10 µg/ml 
ceftazidime for an additional 18 hours.  Surviving E. coli were plated and enumerated.  Statistical 
differences were determined by one-way ANOVA a > b > c > d, P < 0.05.  Data represents one 
experiment with treatment groups run in triplicate. 
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